DK1589107T3 - Immonuglobuliner uden lette kæder - Google Patents

Immonuglobuliner uden lette kæder

Info

Publication number: DK1589107T3
Authority: DK; Denmark
Prior art keywords: immunuglobulins; light chains; antigen binding; polypeptide chains; immunoglobulin
Prior art date: 1992-08-21

Application number

DK05008358.3T

Other languages

English (en)

Inventor

Cecile Casterman

Raymond Hamers

Original Assignee

Univ Bruxelles

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-21

Filing date

1993-08-18

Publication date

2010-04-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26132410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1589107(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-08-21 Priority claimed from EP92402326A external-priority patent/EP0584421A1/en

1993-08-18 Application filed by Univ Bruxelles filed Critical Univ Bruxelles

2010-04-26 Application granted granted Critical

2010-04-26 Publication of DK1589107T3 publication Critical patent/DK1589107T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK05008358.3T 1992-08-21 1993-08-18 Immonuglobuliner uden lette kæder DK1589107T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP92402326A EP0584421A1 (en)	1992-08-21	1992-08-21	Immunoglobulins devoid of light chains
EP93401310		1993-05-21
EP00127968A EP1087013B1 (en)	1992-08-21	1993-08-18	Immunoglobulins devoid of light chains

Publications (1)

Publication Number	Publication Date
DK1589107T3 true DK1589107T3 (da)	2010-04-26

Family

ID=26132410

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
DK05008358.3T DK1589107T3 (da)	1992-08-21	1993-08-18	Immonuglobuliner uden lette kæder
DK04077639.5T DK1498427T3 (da)	1992-08-21	1993-08-18	Immunoglobuliner, som ikke har lette kæder
DK05020889.1T DK1621554T4 (da)	1992-08-21	1993-08-18	Immunoglobuliner blottet for lette kæder
DK93919098.9T DK0656946T4 (da)	1992-08-21	1993-08-18	Immunoglobuliner uden lette kæder
DK00127968T DK1087013T3 (da)	1992-08-21	1993-08-18	Immunoglobuliner uden lette kæder

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
DK04077639.5T DK1498427T3 (da)	1992-08-21	1993-08-18	Immunoglobuliner, som ikke har lette kæder
DK05020889.1T DK1621554T4 (da)	1992-08-21	1993-08-18	Immunoglobuliner blottet for lette kæder
DK93919098.9T DK0656946T4 (da)	1992-08-21	1993-08-18	Immunoglobuliner uden lette kæder
DK00127968T DK1087013T3 (da)	1992-08-21	1993-08-18	Immunoglobuliner uden lette kæder

Country Status (13)

Country	Link
US (5)	US5800988A (da)
EP (6)	EP0656946B2 (da)
JP (4)	JP3444885B2 (da)
AT (5)	ATE420178T1 (da)
AU (1)	AU701578B2 (da)
CA (1)	CA2142331C (da)
DE (6)	DE69334305D1 (da)
DK (5)	DK1589107T3 (da)
ES (5)	ES2325541T3 (da)
FI (3)	FI115462B (da)
GR (1)	GR3037024T3 (da)
PT (5)	PT1621554E (da)
WO (1)	WO1994004678A1 (da)

Families Citing this family (1313)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6765087B1 (en) *	1992-08-21	2004-07-20	Vrije Universiteit Brussel	Immunoglobulins devoid of light chains
DE69427974T2 (de) *	1993-04-29	2001-12-06	Unilever N.V., Rotterdam	Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
EP0739981A1 (en) *	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US20040248201A1 (en) *	1996-06-27	2004-12-09	Serge Muyldermans	Recognition molecules interacting specifically with the active site or cleft of a target molecule
CA2258518C (en) *	1996-06-27	2011-11-22	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Recognition molecules interacting specifically with the active site or cleft of a target molecule
DK0931097T3 (da) *	1996-10-10	2006-01-16	Neose Technologies Inc	Kulhydratoprensning ved anvendelse af omvendt osmose og nanofiltrering
US20030228310A1 (en) *	1996-12-23	2003-12-11	Advanced Biotherapy, Inc.	Treatment of skin diseases
WO1999037681A2 (en) *	1998-01-26	1999-07-29	Unilever Plc	Method for producing antibody fragments
WO1999055369A1 (en) *	1998-04-28	1999-11-04	Smithkline Beecham Corporation	Monoclonal antibodies with reduced immunogenicity
CA2370351A1 (en)	1999-04-22	2000-11-02	Unilever Plc	Inhibition of viral infection using monovalent antigen-binding proteins
US6924359B1 (en) *	1999-07-01	2005-08-02	Yale University	Neovascular-targeted immunoconjugates
EP1196532A1 (en)	1999-07-27	2002-04-17	Unilever N.V.	Bleaching detergent compositions
JP2003509438A (ja) *	1999-09-16	2003-03-11	ユニリーバー・ナームローゼ・ベンノートシヤープ	抗フケ剤の送達システム
US6479280B1 (en) *	1999-09-24	2002-11-12	Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw	Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
EP1088892A1 (en) *	1999-09-24	2001-04-04	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
AU1859201A (en)	1999-11-29	2001-06-12	Unilever Plc	Immobilisation of proteins
EP1118669A3 (en) *	1999-12-17	2001-08-29	Unilever Plc	Production of camelid antibodies in plants
ATE428733T1 (de)	2000-03-14	2009-05-15	Unilever Nv	Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
US6696620B2 (en) *	2000-05-02	2004-02-24	Epicyte Pharmaceutical, Inc.	Immunoglobulin binding protein arrays in eukaryotic cells
US20030190598A1 (en) *	2000-05-26	2003-10-09	Jasmid Tanha	Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2002057445A1 (en) *	2000-05-26	2002-07-25	National Research Council Of Canada	Single-domain brain-targeting antibody fragments derived from llama antibodies
AU2001297872B2 (en) *	2000-11-17	2006-11-09	University Of Rochester	In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20050196755A1 (en) *	2000-11-17	2005-09-08	Maurice Zauderer	In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20060064782A1 (en) *	2000-12-18	2006-03-23	Conopco, Inc.	Production of antibodies
BR0116283A (pt)	2000-12-19	2005-12-13	Unilever Nv	Grânulo de anticorpo, composições detergente, enzimática alvejante de manchas e enzimática de anti-transferência de corante, e, processo para a preparação de um grânulo de anticorpo
US8372954B2 (en) *	2000-12-22	2013-02-12	National Research Council Of Canada	Phage display libraries of human VH fragments
AU2002305914A1 (en)	2001-01-12	2002-10-21	Chiron Corporation	Nucleic acid mucosal immunization
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) *	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
US20050069538A1 (en) *	2003-09-18	2005-03-31	Gregorio Aversa	Therapeutic binding molecules
US20040058445A1 (en) *	2001-04-26	2004-03-25	Ledbetter Jeffrey Alan	Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US6861056B2 (en) *	2001-06-05	2005-03-01	Advanced Biotherapy, Inc.	Compositions and methods for treating hyperimmune response in the eye
US20040086508A1 (en) *	2001-06-05	2004-05-06	Advanced Biotherapy, Inc.	Treatment of organ transplant rejection
US20040062768A1 (en) *	2001-06-05	2004-04-01	Advanced Biotherapy, Inc.	Compositions and methods for treating hyperimmune response in the eye
US20050152902A1 (en) *	2001-06-05	2005-07-14	Advanced Biotherapy, Inc.	Treatment of diabetic retinopathy
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
AU2002360068B2 (en) *	2001-12-21	2009-09-03	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Method for cloning of variable domain sequences
JP2005517674A (ja) *	2002-01-03	2005-06-16	フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー	腫瘍の処置に有用な新規免疫コンジュゲート
CA2472927A1 (en)	2002-01-10	2003-07-17	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	A novel splice variant of myd88 and uses thereof
US7736657B2 (en)	2002-02-10	2010-06-15	Apoxis S.A.	Fusion constructs containing active sections on TNF ligands
US20030219436A1 (en) *	2002-03-15	2003-11-27	Ledbetter Jeffrey A.	Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
DK1517921T3 (da) *	2002-06-28	2006-10-09	Domantis Ltd	Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
KR20110025885A (ko)	2002-07-15	2011-03-11	더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템	포스파티딜에탄올아민에 결합하는 펩타이드, 및 바이러스 감염을 치료하는데 있어서 이의 용도
ATE512364T1 (de)	2002-08-07	2011-06-15	Ablynx Nv	Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
JP4459810B2 (ja)	2002-08-14	2010-04-28	マクロジェニクス，インコーポレーテッド	ＦｃγＲＩＩＢ特異的抗体とその利用法
GB0219720D0 (en) *	2002-08-23	2002-10-02	Univ Aberdeen	Polypeptide
US20040052790A1 (en) *	2002-09-18	2004-03-18	Advanced Biotherapy, Inc.	Treatment of schizophrenia
WO2005044858A1 (en)	2003-11-07	2005-05-19	Ablynx N.V.	Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US9320792B2 (en)	2002-11-08	2016-04-26	Ablynx N.V.	Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2010081856A1 (en)	2009-01-14	2010-07-22	Ablynx Nv	Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en)	2002-11-08	2006-02-16	Karen Silence	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP1558647B1 (en)	2002-11-08	2015-06-10	Ablynx N.V.	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP3299393A1 (en)	2002-11-08	2018-03-28	Ablynx N.V.	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0230203D0 (en) *	2002-12-27	2003-02-05	Domantis Ltd	Fc fusion
EP1437764A1 (en) *	2003-01-10	2004-07-14	S.O.I. Tec Silicon on Insulator Technologies S.A.	A compliant substrate for a heteroepitaxy, a heteroepitaxial structure and a method for fabricating a compliant substrate
NZ540771A (en)	2003-01-10	2009-05-31	Ablynx Nv	Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
AU2004229501B2 (en)	2003-04-11	2011-08-18	Medimmune, Llc	Recombinant IL-9 antibodies and uses thereof
DK1639011T3 (da)	2003-06-30	2009-02-16	Domantis Ltd	Pegylerede enkelt-domæne antistoffer (dAb)
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
PL3095793T3 (pl)	2003-07-28	2020-09-07	Genentech, Inc.	Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A
EP2128270B1 (en)	2003-08-08	2012-10-03	Genenews Inc.	Osteoarthritis biomarkers and uses thereof
WO2005081687A2 (en) *	2003-09-30	2005-09-09	Centocor, Inc.	Human hinge core mimetibodies, compositions, methods and uses
EP1682179A4 (en)	2003-11-05	2008-09-03	Palingen Inc	IMPROVED B-CELL CYTOTOXICITY OF CDIM BINDING ANTIBODY
ES2616337T3 (es) *	2003-12-12	2017-06-12	Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors	Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
WO2005105984A2 (en) *	2004-04-12	2005-11-10	The Trustees Of The University Of Pennsylvania	Culture conditions and growth factors affecting fate determination, self-renewal and expansion of mouse spermatogonial stem cells
CN1942203A (zh) *	2004-06-04	2007-04-04	金克克国际有限公司	使用抗体重链的筛选方法
US20050276806A1 (en) *	2004-06-15	2005-12-15	Advanced Biotherapy, Inc.	Treatment of autism
US20050276807A1 (en) *	2004-06-15	2005-12-15	Advanced Biotherapy, Inc.	Treatment of acne
WO2006008548A2 (en)	2004-07-22	2006-01-26	Erasmus University Medical Centre Rotterdam	Binding molecules
GB2416768A (en) *	2004-07-22	2006-02-08	Univ Erasmus	Heavy chain immunoglobulin complexes
US20060177445A1 (en) *	2004-08-16	2006-08-10	Boris Skurkovich	Treatment of inflammatory skin diseases
US7563443B2 (en)	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
CN101724071A (zh)	2004-10-08	2010-06-09	杜门蒂斯有限公司	抗肿瘤坏死因子受体1的单域抗体及其使用方法
US7462454B2 (en)	2004-10-12	2008-12-09	Advanced Biotherapy, Inc.	Treatment of herpes
BRPI0518151A2 (pt) *	2004-10-13	2009-06-16	Ablynx Nv	polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
US20060121042A1 (en)	2004-10-27	2006-06-08	Medimmune, Inc.	Modulation of antibody specificity by tailoring the affinity to cognate antigens
ATE473446T1 (de)	2005-01-14	2010-07-15	Ablynx Nv	Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
CA2595682A1 (en) *	2005-01-31	2006-08-03	Ablynx N.V.	Method for generating variable domain sequences of heavy chain antibodies
CN103497993A (zh)	2005-02-07	2014-01-08	基因信息公司	轻度骨关节炎生物标志物及其用途
AU2006213686A1 (en)	2005-02-09	2006-08-17	Avi Bio Pharma, Inc.	Antisense composition and method for treating muscle atrophy
JP5032458B2 (ja) *	2005-03-11	2012-09-26	シンジェンタリミテッド	有害生物防除
AU2006239315B2 (en)	2005-04-28	2012-03-01	Ventana Medical Systems, Inc.	Enzymes conjugated to antiobodies via a PEG heterobifuctional linker
US20060246524A1 (en) *	2005-04-28	2006-11-02	Christina Bauer	Nanoparticle conjugates
CN103254309B (zh)	2005-05-18	2017-09-26	埃博灵克斯股份有限公司	针对肿瘤坏死因子α的改进的纳米体TM
CN101213214B (zh)	2005-05-20	2014-06-25	埃博灵克斯股份有限公司	针对冯威勒布兰特因子的单一结构域vhh抗体
DE102005023617A1 (de)	2005-05-21	2006-11-23	Aspre Ag	Verfahren zum Mischen von Farben in einem Display
HUE026303T2 (hu) *	2005-07-25	2016-06-28	Emergent Product Dev Seattle	B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
EP2354160A1 (en)	2005-08-31	2011-08-10	Schering Corporation	Engineered anti-IL-23-antibodies
CN101296706B (zh)	2005-09-01	2011-11-30	先灵公司	Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途
WO2007036021A1 (en) *	2005-09-27	2007-04-05	National Research Council Of Canada	Blood-brain barrier epitopes and uses thereof
CA2624081C (en) *	2005-09-29	2014-09-16	Medimmune, Inc.	Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US7526409B2 (en) *	2005-10-07	2009-04-28	Oracle International Corporation	Automatic performance statistical comparison between two periods
GB0521139D0 (en)	2005-10-18	2005-11-23	Univ Sheffield	Therapeutic agent
TW200730825A (en)	2005-10-21	2007-08-16	Genenews Inc	Method and apparatus for correlating levels of biomarker products with disease
GB0522460D0 (en) *	2005-11-03	2005-12-14	Prendergast Patrick T	Composition and method for the treatment of avian influenza
EP3095467B1 (en) *	2005-11-23	2020-05-06	Ventana Medical Systems, Inc.	Antibody-enzyme conjugate
US10183986B2 (en)	2005-12-15	2019-01-22	Industrial Technology Research Institute	Trimeric collagen scaffold antibodies
EP1983823A1 (en)	2006-01-17	2008-10-29	VIB vzw	Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
WO2007085814A1 (en) *	2006-01-24	2007-08-02	Domantis Limited	Fusion proteins that contain natural junctions
TWI417301B (zh)	2006-02-21	2013-12-01	Wyeth Corp	對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) *	2006-02-21	2007-12-16	Wyeth Corp	Methods of using antibodies against human IL-22
US7504106B2 (en) *	2006-03-14	2009-03-17	Boris Skurkovich	Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
EP1999147A1 (en) *	2006-03-27	2008-12-10	Ablynx N.V.	Medical delivery device for therapeutic proteins based on single domain antibodies
MX2008013397A (es) *	2006-04-21	2009-03-27	Wyeth Corp	Analisis de perfilamiento de expresion diferencial de fenotipos de cultivo celular y usos de los mismos.
RU2008147398A (ru)	2006-05-02	2010-06-10	Актогеникс Н.В. (Be)	Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов
CN105837690A (zh)	2006-06-12	2016-08-10	新兴产品开发西雅图有限公司	具有效应功能的单链多价结合蛋白
EP2037961B1 (en)	2006-06-14	2015-11-11	MacroGenics, Inc.	Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
EP2505209A1 (en)	2006-06-26	2012-10-03	MacroGenics, Inc.	Fcgamma-RIIB-specific antibodies and methods of the use thereof
DK2041270T3 (da)	2006-07-13	2014-01-27	Wyeth Llc	Fremstilling af glycoproteiner
EP2484696B1 (en)	2006-08-28	2017-08-16	Kyowa Hakko Kirin Co., Ltd.	Antagonistic hLIGHT-specific human monoclonal antibodies
EP3028716B1 (en)	2006-10-10	2020-09-16	Regenesance B.V.	Complement inhibition for improved nerve regeneration
GB0621513D0 (en)	2006-10-30	2006-12-06	Domantis Ltd	Novel polypeptides and uses thereof
DK2078197T3 (da)	2006-11-01	2016-05-23	Ventana Med Syst Inc	Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
EP2092080A1 (en)	2006-11-07	2009-08-26	Vib Vzw	Diagnosis and treatment of t-cell acute lymphoblastic leukemia
CA2670471A1 (en)	2006-11-22	2008-06-05	Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation)	Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
JP2010511397A (ja) *	2006-12-05	2010-04-15	アブリンクスエン．ヴェー．	血清タンパク質と結合可能なペプチド
KR20090088950A (ko)	2006-12-14	2009-08-20	쉐링 코포레이션	가공된 항-ｔｓｌｐ 항체
EP2514767A1 (en)	2006-12-19	2012-10-24	Ablynx N.V.	Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2115004A2 (en)	2006-12-19	2009-11-11	Ablynx N.V.	Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US9023352B2 (en)	2007-02-20	2015-05-05	Tufts University	Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
JP2010518839A (ja) *	2007-02-21	2010-06-03	アブリンクスエン．ヴェー．	血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び／もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド
CA2678863A1 (en)	2007-02-23	2008-08-28	Schering Corporation	Engineered anti-il-23p19 antibodies
MX2009009079A (es)	2007-02-23	2009-08-31	Schering Corp	Anticuerpos anti-il-23p19 de ingenieria.
CN101675076B (zh)	2007-02-28	2013-09-18	默沙东公司	工程化的抗il-23r抗体
EP2417974A1 (en)	2007-02-28	2012-02-15	Schering Corporation	Combination therapy for treatment of immune disorders
KR20090127326A (ko)	2007-03-02	2009-12-10	와이어쓰	폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
DK2308514T3 (da)	2007-03-23	2013-09-02	To Bbb Holding B V	Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
TW200902708A (en)	2007-04-23	2009-01-16	Wyeth Corp	Methods of protein production using anti-senescence compounds
CA2685213C (en)	2007-05-04	2017-02-21	Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa	Engineered rabbit antibody variable domains and uses thereof
DK3072525T3 (da)	2007-05-14	2018-04-30	Astrazeneca Ab	Fremgangsmåder til reducering af niveauer af basofile celler
EP3561513A1 (en)	2007-05-23	2019-10-30	Ventana Medical Systems, Inc.	Polymeric carriers for immunohistochemistry and in situ hybridization
EP2602323B1 (en)	2007-06-01	2018-02-28	Open Monoclonal Technology, Inc.	Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
WO2008157299A2 (en) *	2007-06-15	2008-12-24	Wyeth	Differential expression profiling analysis of cell culture phenotypes and uses thereof
JP5240870B2 (ja)	2007-07-03	2013-07-17	アブリンクスエン．ヴェー．	改善した免疫グロブリン配列を提供する方法
EP2170960B1 (en)	2007-07-13	2015-07-29	Bac Ip B.V.	Single-domain antigen-binding proteins that bind mammalian igg
US20100291593A1 (en)	2007-07-13	2010-11-18	Powell William C	Method of identifying diagnostic reagents
EP3327132A3 (en)	2007-08-09	2018-07-18	Wyeth LLC	Use of perfusion to enhance production of fed-batch cell culture in bioreactors
ES2667729T3 (es)	2007-09-26	2018-05-14	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CA2702637A1 (en)	2007-10-22	2009-04-30	Schering Corporation	Fully human anti-vegf antibodies and methods of using
ES2560532T3 (es)	2007-11-02	2016-02-19	Novartis Ag	Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6)
JP5514399B2 (ja) *	2007-11-02	2014-06-04	国立大学法人岡山大学	無機硫黄化合物加水分解酵素の製造方法
WO2010008411A1 (en)	2007-11-09	2010-01-21	The Salk Institute For Biological Studies	Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
CN101970490A (zh)	2007-11-27	2011-02-09	埃博灵克斯股份有限公司	针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
US9308257B2 (en)	2007-11-28	2016-04-12	Medimmune, Llc	Protein formulation
US20090186358A1 (en) *	2007-12-21	2009-07-23	Wyeth	Pathway Analysis of Cell Culture Phenotypes and Uses Thereof
JP5889533B2 (ja)	2008-01-31	2016-03-22	ザガバメントオブザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	改変された抗体定常ドメイン分子
CA2717015A1 (en)	2008-03-05	2009-09-11	Ablynx Nv	Novel antigen binding dimer-complexes, methods of making and uses thereof
GB0809069D0 (en)	2008-05-19	2008-06-25	Univ Leuven Kath	Gene signatures
WO2009121948A2 (en)	2008-04-03	2009-10-08	Vib Vzw	Single domain antibodies capable of modulating bace activity
US9908943B2 (en)	2008-04-03	2018-03-06	Vib Vzw	Single domain antibodies capable of modulating BACE activity
WO2009124931A2 (en)	2008-04-07	2009-10-15	Ablynx Nv	Amino acid sequences directed against the notch pathways and uses thereof
AU2009234277B2 (en)	2008-04-11	2014-12-04	Aptevo Research And Development Llc	CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2009127691A1 (en)	2008-04-17	2009-10-22	Ablynx N.V.	Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
MX2010011957A (es)	2008-05-02	2011-03-04	Novartis Ag Star	Moleculas de union basadas en fibronectina mejoradas y usos de las mismas.
EP2799448A1 (en)	2008-05-22	2014-11-05	Bristol-Myers Squibb Company	Multivalent fibronectin based scaffold domain proteins
US8703490B2 (en)	2008-06-05	2014-04-22	Ventana Medical Systems, Inc.	Compositions comprising nanomaterials and method for using such compositions for histochemical processes
GB2461546B (en) *	2008-07-02	2010-07-07	Argen X Bv	Antigen binding polypeptides
US8444976B2 (en)	2008-07-02	2013-05-21	Argen-X B.V.	Antigen binding polypeptides
US8168759B2 (en)	2008-07-18	2012-05-01	Bristol-Myers Squibb Company	Compositions monovalent for CD28 binding and methods of use
EP2313436B1 (en)	2008-07-22	2014-11-26	Ablynx N.V.	Amino acid sequences directed against multitarget scavenger receptors and polypeptides
WO2010015608A1 (en)	2008-08-05	2010-02-11	Novartis Ag	Compositions and methods for antibodies targeting complement protein c5
US20100136584A1 (en) *	2008-09-22	2010-06-03	Icb International, Inc.	Methods for using antibodies and analogs thereof
WO2010033913A1 (en) *	2008-09-22	2010-03-25	Icb International, Inc.	Antibodies, analogs and uses thereof
US20100075329A1 (en)	2008-09-23	2010-03-25	O'toole Margot	Methods for predicting production of activating signals by cross-linked binding proteins
EP2346900A1 (en)	2008-10-29	2011-07-27	Wyeth LLC	Methods for purification of single domain antigen binding molecules
EP3011953A1 (en)	2008-10-29	2016-04-27	Ablynx N.V.	Stabilised formulations of single domain antigen binding molecules
CA2747644C (en)	2008-12-19	2023-01-24	Ablynx N.V.	Method for generation of immunoglobulin sequences
EP2379710A1 (en)	2008-12-19	2011-10-26	Schering Corporation	Feed supplement for mammalian cell culture and methods of use
US20100189919A1 (en) *	2009-01-27	2010-07-29	Xerox Corporation	Imaging System And Process Using Monoclonal Antibodies
CA2750520C (en)	2009-02-04	2017-12-05	Molecular Innovations	Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
US10005830B2 (en)	2009-03-05	2018-06-26	Ablynx N.V.	Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP2230515B1 (en) *	2009-03-16	2014-12-17	Agilent Technologies, Inc.	Passivation of surfaces after ligand coupling
GB0905023D0 (en)	2009-03-24	2009-05-06	Univ Erasmus Medical Ct	Binding molecules
JP6159528B2 (ja)	2009-03-24	2017-07-05	ワイス・エルエルシー	高濃縮のタンパク質治療薬を生成するための膜蒸発
EP2417163B1 (en)	2009-04-10	2019-02-27	Ablynx N.V.	Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
NO2424895T3 (da)	2009-04-27	2018-02-03
BRPI1016055A2 (pt)	2009-04-27	2016-05-10	Novartis Ag	composição e métodos de uso para anticorpos terapêuticos específicos para a subunidade beta i do receptor de il-12
DK2982690T3 (da)	2009-04-30	2021-04-12	Ablynx Nv	Fremgangsmåde til fremstilling af domæne-antistoffer
EP2432499A2 (en)	2009-05-20	2012-03-28	Schering Corporation	Modulation of pilr receptors to treat microbial infections
MX340541B (es)	2009-06-05	2016-07-13	Alblynx Nv	Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
US9290577B2 (en)	2009-07-03	2016-03-22	Avipep Pty Limited	Immuno-conjugates and methods for producing them
HUE051430T2 (hu)	2009-07-10	2021-03-01	Ablynx Nv	Eljárás variábilis domének elõállítására
CA2768330A1 (en)	2009-07-28	2011-02-03	F. Hoffmann-La Roche Ag	Non-invasive in vivo optical imaging method
EP2459594A1 (en)	2009-07-31	2012-06-06	N.V. Organon	Fully human antibodies to btla
WO2011018421A1 (en)	2009-08-10	2011-02-17	Morphosys Ag	Novel screening strategies for the identification of binders
US9255148B2 (en)	2009-09-03	2016-02-09	Cancer Research Technology Limited	CLEC14A inhibitors
CA2772613C (en)	2009-09-03	2020-03-10	Schering Corporation	Anti-gitr antibodies
PT2473528E (pt)	2009-09-03	2015-03-04	Ablynx NV	Formulações estáveis de polipéptidos e seus usos
WO2011029823A1 (en)	2009-09-09	2011-03-17	Novartis Ag	Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
UY32917A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Moléculas de unión a dll-4
US20110172398A1 (en)	2009-10-02	2011-07-14	Boehringer Ingelheim International Gmbh	Bispecific binding molecules for anti-angiogenesis therapy
US20110117113A1 (en)	2009-10-09	2011-05-19	Gerald Beste	Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
WO2011045079A1 (en)	2009-10-15	2011-04-21	Intercell Ag	Hepatitis b virus specific human antibodies
WO2011049449A1 (en)	2009-10-22	2011-04-28	University Of Twente	Vhh for application in tissue repair, organ regeneration, organ replacement and tissue engineering
WO2011050242A1 (en)	2009-10-23	2011-04-28	Millennium Pharmaceuticals, Inc.	Anti-gcc antibody molecules and related compositions and methods
ES2860453T3 (es)	2009-10-30	2021-10-05	Novartis Ag	Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
WO2011051327A2 (en)	2009-10-30	2011-05-05	Novartis Ag	Small antibody-like single chain proteins
WO2011051466A1 (en)	2009-11-02	2011-05-05	Novartis Ag	Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011056772A1 (en)	2009-11-04	2011-05-12	Schering Corporation	Engineered anti-tslp antibody
CN102640001A (zh)	2009-11-05	2012-08-15	诺瓦提斯公司	预测纤维化进展的生物标记物
US9644022B2 (en)	2009-11-30	2017-05-09	Ablynx N.V.	Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US8754287B2 (en)	2009-12-10	2014-06-17	Regeneron Pharmaceuticals, Inc.	Mice that make heavy chain antibodies
WO2011072266A2 (en)	2009-12-11	2011-06-16	Atyr Pharma, Inc.	Aminoacyl trna synthetases for modulating hematopoiesis
US8962807B2 (en)	2009-12-14	2015-02-24	Ablynx N.V.	Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2011084357A1 (en)	2009-12-17	2011-07-14	Schering Corporation	Modulation of pilr to treat immune disorders
SG181814A1 (en)	2009-12-23	2012-07-30	Avipep Pty Ltd	Immuno-conjugates and methods for producing them 2
WO2011083140A1 (en)	2010-01-08	2011-07-14	Ablynx Nv	Immunoglobulin single variable domain directed against human cxcr4
TWI513466B (zh)	2010-01-20	2015-12-21	Boehringer Ingelheim Int	抗凝血劑解毒劑
WO2011095545A1 (en)	2010-02-05	2011-08-11	Ablynx Nv	Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
JP2013519869A (ja)	2010-02-10	2013-05-30	ノバルティスアーゲー	筋肉成長のための方法および化合物
EP2533814A2 (en)	2010-02-11	2012-12-19	Ablynx N.V.	Delivery of immunoglobulin variable domains and constructs thereof
HRP20191071T1 (hr)	2010-02-11	2019-09-20	Ablynx N.V.	Postupci i pripravci za pripremu aerosola
WO2011106583A1 (en)	2010-02-26	2011-09-01	Ventana Medical Systems, Inc.	Polytag probes
WO2011107507A1 (en)	2010-03-03	2011-09-09	Boehringer Ingelheim International Gmbh	Biparatopic abeta binding polypeptides
WO2011117423A1 (en)	2010-03-26	2011-09-29	Ablynx N.V.	Immunoglobulin single variable domains directed against cxcr7
US20130041349A1 (en)	2010-03-26	2013-02-14	Westfaelische Wilhelms-Universitaet Muenster	Substitute therapy for glucocorticoids
US9101674B2 (en)	2010-03-29	2015-08-11	Vib Vzw	Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en)	2010-03-29	2017-01-31	Vib Vzw	Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
WO2011124612A1 (en)	2010-04-06	2011-10-13	Vib Vzw	Specific delivery of agrochemicals
GB201105584D0 (en)	2011-04-01	2011-05-18	Imp Innovations Ltd	Cancer methods
CA2796087A1 (en)	2010-04-20	2011-10-27	Ventana Medical Systems, Inc.	Two-color chromogenic in situ hybridization
JP6066900B2 (ja)	2010-04-26	2017-01-25	エータイアーファーマ，インコーポレイテッド	システイニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8961960B2 (en)	2010-04-27	2015-02-24	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
JP6008837B2 (ja)	2010-04-28	2016-10-19	エータイアーファーマ，インコーポレイテッド	アラニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011139907A2 (en)	2010-04-29	2011-11-10	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
US8986680B2 (en)	2010-04-29	2015-03-24	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
KR101800913B1 (ko)	2010-04-30	2017-12-20	알렉시온 파마슈티칼스, 인코포레이티드	항-c5a 항체들과 이 항체들을 이용하는 방법
JP6008841B2 (ja)	2010-05-03	2016-10-19	エータイアーファーマ，インコーポレイテッド	メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011248227B2 (en)	2010-05-03	2016-12-01	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
US8961961B2 (en)	2010-05-03	2015-02-24	a Tyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
EP2566499B1 (en)	2010-05-04	2017-01-25	aTyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
EP2566967B1 (en)	2010-05-04	2016-07-06	The Brigham and Women's Hospital, Inc.	Cadherin-11 antagonist for the treatment of fibrosis
US8877188B2 (en)	2010-05-04	2014-11-04	The Brigham And Women's Hospital, Inc.	Detection and treatment of non-dermal fibrosis
US9290573B2 (en)	2010-05-06	2016-03-22	Novartis Ag	Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
ES2659406T3 (es)	2010-05-06	2018-03-15	Novartis Ag	Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
EP2567234B1 (en)	2010-05-07	2018-09-19	F.Hoffmann-La Roche Ag	Diagnostic method for the detection of cells ex vivo
EP2568996B1 (en)	2010-05-14	2017-10-04	aTyr Pharma, Inc.	Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
SG185354A1 (en)	2010-05-20	2012-12-28	Ablynx Nv	Biological materials related to her3
CN103096913B (zh)	2010-05-27	2017-07-18	Atyr 医药公司	与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2585110A4 (en)	2010-06-22	2014-01-22	Univ Colorado Regents	ANTIBODIES AGAINST THE C3D FRAGMENT OF THE COMPLEMENT COMPONENT 3
WO2011161263A1 (en)	2010-06-25	2011-12-29	Ablynx Nv	Pharmaceutical compositions for cutaneous administration
AU2011274369A1 (en)	2010-07-02	2012-12-06	Ventana Medical Systems, Inc.	Hapten conjugates for target detection
US20130149297A1 (en)	2010-07-02	2013-06-13	Vib Vzw	Role of fragile x mental retardation gene and protein in cancer metastasis
CA2804416C (en)	2010-07-12	2020-04-28	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
AU2011277983C1 (en)	2010-07-16	2016-09-29	Ablynx Nv	Modified single domain antigen binding molecules and uses thereof
GB201014715D0 (en)	2010-09-06	2010-10-20	Vib Vzw	Nanobodies stabilizing functional conformational states of GPCRS
GB201012845D0 (en)	2010-07-30	2010-09-15	Vib Vzw	Inhibition of dicer function for treatment of cancer
RU2612903C2 (ru)	2010-08-02	2017-03-13	Ридженерон Фармасьютикалз, Инк.	Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
EP2606055B1 (en)	2010-08-16	2015-06-03	Ventana Medical Systems, Inc.	Substrates for chromogenic detection and methods of use in detection assays and kits
JP2013535981A (ja)	2010-08-20	2013-09-19	ワイス・エルエルシー	成長因子不含適合細胞の細胞培養
PL2606070T3 (pl)	2010-08-20	2017-06-30	Novartis Ag	Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
JP5964304B2 (ja)	2010-08-25	2016-08-03	エータイアーファーマ，インコーポレイテッド	チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
HUE036251T2 (hu)	2010-08-26	2018-06-28	Agrosavfe N V	Kitinféle poliszacharid antigént kötõ fehérjék
US20130224226A1 (en)	2010-08-26	2013-08-29	Agrosavfe N.V.	Insect binding antibodies
US20120225081A1 (en)	2010-09-03	2012-09-06	Boehringer Ingelheim International Gmbh	Vegf-binding molecules
US20120244141A1 (en)	2010-09-28	2012-09-27	Boehringer Ingelheim International Gmbh	Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2012042026A1 (en)	2010-09-30	2012-04-05	Ablynx Nv	Biological materials related to c-met
JP2013543384A (ja)	2010-10-05	2013-12-05	ノバルティスアーゲー	抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
EP3279214B1 (en)	2010-10-29	2024-10-09	Ablynx NV	Method for the production of immunoglobulin single variable domains
GB201018602D0 (en)	2010-11-04	2010-12-22	Vib Vzw	MMP8 inactivating antigen binding proteins
SG189957A1 (en)	2010-11-05	2013-06-28	Morphotek Inc	Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
KR101650995B1 (ko)	2010-11-08	2016-08-25	노파르티스 아게	Ｃｘｃｒ２ 결합 폴리펩티드
WO2012084895A2 (en)	2010-12-20	2012-06-28	Universiteit Gent	Crystal structure of flt3 ligand-receptor complex
WO2012089814A1 (en)	2010-12-30	2012-07-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antigen binding formats for use in therapeutic treatments or diagnostic assays
ES2593464T3 (es)	2010-12-30	2016-12-09	Ventana Medical Systems, Inc.	Deposición potenciada de cromógenos utilizando análogos de pirimidina
AR085091A1 (es)	2011-01-26	2013-09-11	Kolltan Pharmaceuticals Inc	Anticuerpos anti-kit y sus usos
CN103459427B (zh)	2011-02-01	2018-03-30	Bac Ip私人有限公司	针对人IgG抗体的CH1结构域中表位的抗原结合蛋白
JP6150734B2 (ja)	2011-02-03	2017-06-21	アレクシオンファーマシューティカルズ，インコーポレイテッド	同種移植片の生存を長期化するための抗ｃｄ２００抗体の使用
JP6385060B2 (ja)	2011-03-07	2018-09-05	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	治療的に活性な抗体のインビボにおける選択
US20140099264A1 (en)	2011-03-07	2014-04-10	F. Hoffman-La Roche Ag	Means and methods for in vivo testing of therapeutic antibodies
US9562259B2 (en)	2011-03-14	2017-02-07	Ventana Medical Systems, Inc.	Method of analyzing chromosomal inversions
US9624294B2 (en)	2011-03-14	2017-04-18	Cellmid Limited	Antibody recognizing N-domain of midkine
US20150158948A9 (en)	2011-03-28	2015-06-11	Francis Descamps	Bispecific anti-cxcr7 immunoglobulin single variable domains
EP2691415B1 (en)	2011-03-28	2018-07-11	Ablynx N.V.	Method for producing solid formulations comprising immunoglobulin single variable domains
WO2012131053A1 (en)	2011-03-30	2012-10-04	Ablynx Nv	Methods of treating immune disorders with single domain antibodies against tnf-alpha
PH12013501924A1 (en)	2011-03-30	2017-10-25	Boehringer Ingelheim Int	Anticoagulant antidotes
US9220776B2 (en)	2011-03-31	2015-12-29	Merck Sharp & Dohme Corp.	Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en)	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2
PL2699264T3 (pl)	2011-04-20	2018-08-31	Medimmune, Llc	Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP3590950A1 (en)	2011-05-09	2020-01-08	Ablynx NV	Method for the production of immunoglobulin single varible domains
EP2710042A2 (en)	2011-05-16	2014-03-26	Fabion Pharmaceuticals, Inc.	Multi-specific fab fusion proteins and methods of use
RU2661677C2 (ru)	2011-05-27	2018-07-18	Аблинкс Нв	Ингибирование резорбции кости с помощью связывающих rank-l пептидов
US9580480B2 (en)	2011-05-31	2017-02-28	Massachusetts Institute Of Technology	Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
CA2838246C (en)	2011-06-13	2018-07-10	Csl Limited	Antibodies against g-csfr and uses thereof
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
ES2662372T3 (es)	2011-06-21	2018-04-06	Vib Vzw	Dominios de unión dirigidos contra complejos GPCR:proteína G y usos derivados de los mismos
EP2723771B1 (en)	2011-06-23	2019-09-11	Ablynx NV	Serum albumin binding proteins
JP2014525736A (ja)	2011-06-23	2014-10-02	アブリンクスエン．ヴェー．	ＩｇＥに対する免疫グロブリン単一可変ドメイン
PL2726099T3 (pl)	2011-07-01	2018-12-31	Novartis Ag	Sposób leczenia zaburzeń metabolicznych
GB201112056D0 (en)	2011-07-14	2011-08-31	Univ Leuven Kath	Antibodies
WO2013010955A1 (en)	2011-07-15	2013-01-24	Morphosys Ag	Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
PE20141522A1 (es)	2011-08-17	2014-11-17	Glaxo Group Ltd	Proteinas y peptidos modificados
WO2013033073A1 (en)	2011-08-31	2013-03-07	Ventana Medical Systems, Inc.	Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration
GB201115529D0 (en)	2011-09-08	2011-10-26	Imp Innovations Ltd	Antibodies, uses and methods
EP2753644A1 (en)	2011-09-09	2014-07-16	Universiteit Utrecht Holding B.V.	Broadly neutralizing vhh against hiv-1
EP2757875B2 (en)	2011-09-19	2023-03-22	Kymab Limited	Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US20140235492A1 (en)	2011-09-20	2014-08-21	Institut National De La Sante Et De La Recherche Medicate (Inserm)	Methods for preparing single domain antibody microarrays
WO2013041722A1 (en)	2011-09-23	2013-03-28	Ablynx Nv	Prolonged inhibition of interleukin-6 mediated signaling
WO2013045916A1 (en)	2011-09-26	2013-04-04	Kymab Limited	Chimaeric surrogate light chains (slc) comprising human vpreb
EP2747783B1 (en)	2011-09-30	2017-06-14	Ablynx N.V.	Biological materials related to c-met
US20130085139A1 (en)	2011-10-04	2013-04-04	Royal Holloway And Bedford New College	Oligomers
JP2014530816A (ja)	2011-10-14	2014-11-20	ノバルティスアーゲー	Ｗｎｔ経路関連疾患のための抗体および方法
US9127056B2 (en)	2011-10-17	2015-09-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
AU2012327878A1 (en)	2011-10-28	2014-05-29	Patrys Limited	PAT-LM1 epitopes and methods for using same
GB2496375A (en)	2011-10-28	2013-05-15	Kymab Ltd	A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
SG11201401649VA (en)	2011-11-11	2014-07-30	Ucb Pharma Sa	Albumin binding antibodies and binding fragments thereof
WO2013079606A1 (en)	2011-12-01	2013-06-06	Ventana Medical Systems, Inc.	Automated dual stain of mirna and protein targets
GB201122047D0 (en)	2011-12-21	2012-02-01	Kymab Ltd	Transgenic animals
EP2785741A1 (en)	2011-12-02	2014-10-08	Cancer Research Technology Limited	Antibodies against hgf - receptor and uses
EP2788382A2 (en)	2011-12-05	2014-10-15	Novartis AG	Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
AU2012349735B2 (en)	2011-12-05	2016-05-19	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (HER3)
CA2859493A1 (en)	2011-12-21	2013-06-27	Novartis Ag	Compositions and methods for antibodies targeting factor p
US10112988B2 (en)	2012-01-09	2018-10-30	Icb International, Inc.	Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en)	2012-01-09	2018-10-30	Icb International, Inc.	Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
WO2013108126A2 (en)	2012-01-16	2013-07-25	University Of Oslo	Methyltransferases and uses thereof
CA2862222A1 (en)	2012-01-20	2013-07-25	Genzyme Corporation	Anti-cxcr3 antibodies
US20150301068A1 (en)	2012-01-30	2015-10-22	Vib Vzw	Means and method for diagnosis and treatment of alzheimer's disease
WO2013121042A1 (en)	2012-02-16	2013-08-22	Vib Vzw	PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
UA115781C2 (uk)	2012-02-27	2017-12-26	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Cx3cr1-зв'язуючий поліпептид
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
WO2013148498A1 (en)	2012-03-27	2013-10-03	Ventana Medical Systems, Inc.	Signaling conjugates and methods of use
CA2865464C (en)	2012-03-30	2022-07-12	Boehringer Ingelheim International Gmbh	Ang2-binding molecules
US9156915B2 (en)	2012-04-26	2015-10-13	Thomas Jefferson University	Anti-GCC antibody molecules
US9328174B2 (en)	2012-05-09	2016-05-03	Novartis Ag	Chemokine receptor binding polypeptides
CA2874309C (en)	2012-05-24	2021-06-15	Vib Vzw	Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
EP2687595B1 (en)	2012-07-19	2018-05-30	Laboratoire Français du Fractionnement et des Biotechnologies	Method for purifying transgenic factor VII
SG11201500489YA (en)	2012-07-25	2015-02-27	Kolltan Pharmaceuticals Inc	Anti-kit antibodies and uses thereof
WO2014018535A1 (en)	2012-07-25	2014-01-30	Salk Institute For Biological Studies	Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
EP2890720B1 (en)	2012-08-30	2019-07-17	The General Hospital Corporation	Compositions and methods for treating cancer
UA118441C2 (uk)	2012-10-08	2019-01-25	Протена Біосаєнсиз Лімітед	Антитіло, що розпізнає альфа-синуклеїн
HK1213794A1 (zh)	2012-10-09	2016-07-15	Biogen Ma Inc.	联合治疗及用於治疗脱髓鞘病症的用途
BR112015011061B1 (pt)	2012-11-20	2022-09-27	Novartis Ag	Cassete de expressão adequado para expressão de um polipeptídeo de interesse, vetor de expressão, métodos para produzir uma célula hospedeira eucariótica e um polipeptídeo de interesse, e uso de uma sequência 5'utr em combinação com uma sequência líder de secreção de hcd33 em um cassete de expressão
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
HRP20210517T1 (hr)	2012-12-05	2021-05-14	Novartis Ag	Pripravci i postupci za protutijela usmjerena na epo
WO2014087010A1 (en)	2012-12-07	2014-06-12	Ablynx N.V.	IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
PT2931030T (pt)	2012-12-14	2020-08-03	Open Monoclonal Tech Inc	Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
KR20150095684A (ko)	2012-12-18	2015-08-21	노파르티스 아게	히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
EP2934575A2 (en)	2012-12-19	2015-10-28	Amplimmune, Inc.	B7-h4 specific antibodies, and compositions and methods of use thereof
AU2013204922B2 (en)	2012-12-20	2015-05-14	Celgene Corporation	Chimeric antigen receptors
AR093984A1 (es)	2012-12-21	2015-07-01	Merck Sharp & Dohme	Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
MX2015008117A (es)	2012-12-21	2016-03-31	Amplimmune Inc	Anticuerpos anti-h7cr.
CN105102478A (zh)	2013-01-30	2015-11-25	弗拉芒区生物技术研究所	用于筛选和药物发现目的的新型嵌合多肽
WO2014120916A1 (en)	2013-02-01	2014-08-07	Bristol-Myers Squibb Company	Pegylated domain antibodies monovalent for cd28 binding and methods of use
EP3590578A1 (en)	2013-02-05	2020-01-08	VIB vzw	Muscarinic acetylcholine receptor binding agents and uses thereof
EP2953971B1 (en)	2013-02-07	2023-03-01	CSL Limited	Il-11r binding proteins and uses thereof
AP2015008584A0 (en)	2013-02-08	2015-07-31	Novartis Ag	Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
RU2015140915A (ru)	2013-02-26	2017-04-03	Роше Гликарт Аг	Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
EP2962100B1 (en)	2013-02-28	2021-07-28	Caprion Proteomics Inc.	Tuberculosis biomarkers and uses thereof
EP3764084A1 (en)	2013-03-12	2021-01-13	Ventana Medical Systems, Inc.	Digitally enhanced microscopy for multiplexed histology
JP6674888B2 (ja)	2013-03-13	2020-04-01	プロセナバイオサイエンシーズリミテッド	タウ免疫療法
WO2014159239A2 (en)	2013-03-14	2014-10-02	Novartis Ag	Antibodies against notch 3
CA2906259C (en)	2013-03-15	2022-12-06	Vib Vzw	Anti-mmr single variable domains for prognosis and monitoring of cardiovascular diseases
EP4079760A3 (en)	2013-03-15	2023-01-25	Sanofi Pasteur Inc.	Antibodies against clostridium difficile toxins and methods of using the same
CN105518018B (zh)	2013-03-15	2020-04-03	细胞基因公司	修饰的t淋巴细胞
EP2970426B1 (en)	2013-03-15	2019-08-28	Michael C. Milone	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2014141192A1 (en)	2013-03-15	2014-09-18	Erasmus University Medical Center	Generation of heavy chain-only antibodies
JP6574754B2 (ja)	2013-03-19	2019-09-11	ベイジンシェノゲンファーマグループリミテッド	エストロゲン受容体関連疾患を処置するための抗体及び方法
PL2992101T3 (pl)	2013-04-29	2019-05-31	Agrosavfe Nv	Kompozycje agrochemiczne zawierające przeciwciała wiążące się ze sfingolipidami
AR096236A1 (es)	2013-05-09	2015-12-16	The Us Secretary Dept Of Health And Human Services Nat Inst Of Health Office Of Tech Transfer	Anticuerpos de dominio simple vhh dirigidos a norovirus gi.1 y gii.4 y sus usos
NL1040254C2 (en)	2013-05-17	2014-11-24	Ablynx Nv	Stable formulations of immunoglobulin single variable domains and uses thereof.
JP6682426B2 (ja)	2013-05-24	2020-04-15	メディミューン，エルエルシー	抗ｂ７−ｈ５抗体およびその使用
WO2014194293A1 (en)	2013-05-30	2014-12-04	Amplimmune, Inc.	Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
SG11201509982UA (da)	2013-06-06	2016-04-28	Igenica Biotherapeutics Inc
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9562101B2 (en)	2013-06-21	2017-02-07	Novartis Ag	Lectin-like oxidized LDL receptor 1 antibodies and methods of use
EP3013356B1 (en)	2013-06-27	2018-10-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases
EP3016973A1 (en)	2013-07-05	2016-05-11	INSERM - Institut National de la Santé et de la Recherche Médicale	Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
US9951131B2 (en)	2013-07-12	2018-04-24	Prothena Biosciences Limited	Antibodies that recognize IAPP
US9850302B2 (en)	2013-07-12	2017-12-26	Prothena Biosciences Limited	Antibodies that recognize IAPP
AU2014306002B2 (en)	2013-08-07	2017-05-25	Alexion Pharmaceuticals, Inc.	Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
TW201536318A (zh)	2013-08-14	2015-10-01	Novartis Ag	治療偶發性包涵體肌炎之方法
AR097306A1 (es)	2013-08-20	2016-03-02	Merck Sharp & Dohme	Modulación de la inmunidad tumoral
DK3074038T3 (da)	2013-11-28	2019-03-11	Csl Ltd	Fremgangsmåde til behandling af diabetisk nephropati
EP2883883A1 (en)	2013-12-16	2015-06-17	Cardio3 Biosciences S.A.	Therapeutic targets and agents useful in treating ischemia reperfusion injury
JP6553618B2 (ja)	2013-12-18	2019-07-31	シーエスエルリミティド	創傷を治療する方法
CA3225453A1 (en)	2013-12-19	2015-06-25	Novartis Ag	Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en)	2013-12-20	2024-06-05	Novartis AG	Regulatable chimeric antigen receptor
CA2932515C (en)	2013-12-20	2023-08-01	Intervet International B.V.	Caninized antibodies
WO2015100409A2 (en)	2013-12-26	2015-07-02	Tufts University	Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015121092A1 (en)	2014-01-30	2015-08-20	Vib Vzw	Opioid receptor binding agents and uses thereof
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN106211773B (zh)	2014-02-11	2021-09-03	威特拉公司	用于登革病毒的抗体分子及其应用
JP2017506640A (ja)	2014-02-14	2017-03-09	セントローズ，エルエルシー	細胞外標的化薬物共役体
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
NZ631007A (en)	2014-03-07	2015-10-30	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
ME03558B (me)	2014-03-14	2020-07-20	Novartis Ag	Molekuli anti-lag-3 antiтela i njihove upotrebe
WO2015142675A2 (en)	2014-03-15	2015-09-24	Novartis Ag	Treatment of cancer using chimeric antigen receptor
ES2857226T3 (es)	2014-03-15	2021-09-28	Novartis Ag	Receptor de antígeno quimérico regulable
WO2015143406A2 (en)	2014-03-21	2015-09-24	Regeneron Pharmaceuticals, Inc.	Vl antigen binding proteins exhibiting distinct binding characteristics
RU2016141307A (ru)	2014-03-21	2018-04-24	Регенерон Фармасьютикалз, Инк.	Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
WO2015155694A1 (en)	2014-04-08	2015-10-15	Prothena Biosciences Limited	Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TW201622746A (zh)	2014-04-24	2016-07-01	諾華公司	改善或加速髖部骨折術後身體復原之方法
SI3689899T1 (sl)	2014-04-25	2022-01-31	2Seventy Bio, Inc.	MND promotor kimeričnih antigenskih receptorjev
EP3738597A1 (en)	2014-04-25	2020-11-18	Bluebird Bio, Inc.	Improved methods for manufacturing adoptive cell therapies
US9388239B2 (en)	2014-05-01	2016-07-12	Consejo Nacional De Investigation Cientifica	Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
KR20250099289A (ko)	2014-05-16	2025-07-01	아블린쓰 엔.브이.	개선된 면역글로불린 가변 도메인
PT3248986T (pt)	2014-05-16	2022-04-05	Ablynx Nv	Domínios variáveis de imunoglobulina
SMT202100116T1 (it)	2014-05-28	2021-05-07	Agenus Inc	Anticorpi anti-gitr e metodi di utilizzo degli stessi
NZ726989A (en)	2014-06-06	2020-08-28	Bluebird Bio Inc	Improved t cell compositions
NL2013007B1 (en)	2014-06-16	2016-07-05	Ablynx Nv	Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en)	2014-10-21	2016-10-05	Ablynx Nv	KV1.3 Binding immunoglobulins.
WO2015198240A2 (en)	2014-06-25	2015-12-30	Novartis Ag	Compositions and methods for long acting proteins
US20170290876A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Compositions and methods for long acting proteins
US20170291939A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Antibodies specific for il-17a fused to hyaluronan binding peptide tags
JP2017528433A (ja)	2014-07-21	2017-09-28	ノバルティスアーゲー	低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
WO2016014565A2 (en)	2014-07-21	2016-01-28	Novartis Ag	Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014553A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Sortase synthesized chimeric antigen receptors
BR112017001242A2 (pt)	2014-07-21	2017-12-05	Novartis Ag	tratamento de câncer usando um receptor antigênico quimérico a cd33
CA2955554C (en)	2014-07-22	2022-07-05	Vib Vzw	Methods to select for agents that stabilize protein complexes
SG10201900455YA (en)	2014-07-24	2019-02-27	Bluebird Bio Inc	Bcma chimeric antigen receptors
WO2016016329A1 (en)	2014-07-29	2016-02-04	Vrije Universiteit Brussel	Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
CN106573983B (zh)	2014-07-29	2018-05-25	布鲁塞尔自由大学	用于在癌症的预防和/或治疗中使用的放射性标记的抗体片段
US20170209492A1 (en)	2014-07-31	2017-07-27	Novartis Ag	Subset-optimized chimeric antigen receptor-containing t-cells
WO2016020882A2 (en)	2014-08-07	2016-02-11	Novartis Ag	Angiopoetin-like 4 (angptl4) antibodies and methods of use
SG10201805646WA (en)	2014-08-07	2018-08-30	Novartis Ag	Angiopoietin-like 4 antibodies and methods of use
JP6919118B2 (ja)	2014-08-14	2021-08-18	ノバルティスアーゲー	ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
KR102050082B1 (ko)	2014-08-19	2019-11-29	머크 샤프 앤드 돔 코포레이션	항-tigit 항체
JO3663B1 (ar)	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MY189028A (en)	2014-08-19	2022-01-20	Novartis Ag	Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
KR20170060042A (ko)	2014-09-13	2017-05-31	노파르티스 아게	Alk 억제제의 조합 요법
CA2961636A1 (en)	2014-09-17	2016-03-24	Boris ENGELS	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EA201790737A1 (ru)	2014-10-03	2017-08-31	Новартис Аг	Комбинированная терапия
KR20230042391A (ko)	2014-10-03	2023-03-28	나노틱스 엘엘씨	가용성 생물분자의 생물학적 활성을 억제하기 위한 조성물 및 방법
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
RU2017115670A (ru)	2014-10-10	2018-11-15	Аблинкс Н.В.	Лечение инфекции рсв
SI3204095T1 (sl)	2014-10-10	2019-08-30	Ablynx N.V.	Inhalacijska naprava za uporabo pri zdravljenju bolezni dihal z aerosolom
MX389663B (es)	2014-10-14	2025-03-20	Novartis Ag	Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
WO2016061632A1 (en)	2014-10-23	2016-04-28	La Trobe University	Fn14-binding proteins and uses thereof
BR112017009330A2 (pt)	2014-11-05	2017-12-19	Agrosavfe N V	planta transgênica que compreende um polinucleotídeo que codifica um domínio variável de anticorpo de cadeia pesada
US20180334490A1 (en)	2014-12-03	2018-11-22	Qilong H. Wu	Methods for b cell preconditioning in car therapy
US11001625B2 (en)	2014-12-10	2021-05-11	Tufts University	VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
EP3333191B1 (en)	2014-12-11	2020-09-09	Pierre Fabre Médicament	Anti-c10orf54 antibodies and uses thereof
NZ733025A (en)	2014-12-12	2022-01-28	2Seventy Bio Inc	Bcma chimeric antigen receptors
WO2016094834A2 (en)	2014-12-12	2016-06-16	Alexion Pharmaceuticals, Inc.	A method for treating a complement mediated disorder caused by an infectious agent in a patient
JP6862343B2 (ja)	2014-12-19	2021-04-21	アブリンクスエン．ヴェー．	システイン結合ナノボディダイマー
WO2016100882A1 (en)	2014-12-19	2016-06-23	Novartis Ag	Combination therapies
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
AU2015367224B2 (en)	2014-12-19	2020-12-10	Monash University	IL-21 antibodies
WO2016106221A1 (en)	2014-12-22	2016-06-30	The Rockefeller University	Anti-mertk agonistic antibodies and uses thereof
IL303247A (en)	2014-12-29	2023-07-01	Novartis Ag	Methods for preparing cells expressing a chimeric receptor antigen
EP3240569A4 (en)	2014-12-30	2018-05-30	Celgene Corporation	Anti-cd47 antibodies and uses thereof
CA2972757A1 (en)	2014-12-31	2016-07-07	Arthur M. Krieg	Combination tumor immunotherapy
AU2016205197B2 (en)	2015-01-08	2021-10-21	Biogen Ma Inc.	LINGO-1 antagonists and uses for treatment of demyelinating disorders
GB201501004D0 (en)	2015-01-21	2015-03-04	Cancer Rec Tech Ltd	Inhibitors
WO2016126608A1 (en)	2015-02-02	2016-08-11	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
ES2791950T3 (es)	2015-02-03	2020-11-06	Ventana Med Syst Inc	Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1)
WO2016124568A1 (en)	2015-02-03	2016-08-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-rho gtpase conformational single domain antibodies and uses thereof
WO2016128549A1 (en)	2015-02-13	2016-08-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
WO2016138160A1 (en)	2015-02-24	2016-09-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2016135041A1 (en)	2015-02-26	2016-09-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Fusion proteins and antibodies comprising thereof for promoting apoptosis
EP3061826A1 (en)	2015-02-27	2016-08-31	Novartis AG	Flavivirus replicons
ES2937020T3 (es)	2015-03-03	2023-03-23	Kymab Ltd	Anticuerpos, usos y métodos
MX391249B (es)	2015-03-17	2025-03-21	Memorial Sloan Kettering Cancer Center	Anticuerpos anti-muc16 y sus usos.
MA41795A (fr)	2015-03-18	2018-01-23	Sarepta Therapeutics Inc	Exclusion d'un exon induite par des composés antisens dans la myostatine
US11111314B2 (en)	2015-03-19	2021-09-07	Regeneron Pharmaceuticals, Inc.	Non-human animals that select for light chain variable regions that bind antigen
ES2721781T3 (es)	2015-03-25	2019-08-05	Alexion Pharma Inc	Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa
WO2016151558A1 (en)	2015-03-25	2016-09-29	Alexion Pharmaceuticals, Inc.	A method for measuring the protease activity of factor d of the alternative complement pathway
HK1250040A1 (zh)	2015-03-31	2018-11-23	Sorriso Pharmaceuticals, Inc.	多肽
CA2981098A1 (en)	2015-03-31	2016-10-06	Vhsquared Limited	Peptide construct having a protease-cleavable linker
JP6895421B2 (ja)	2015-03-31	2021-06-30	ブイエイチスクエアードリミテッド	ポリペプチド
WO2016156588A1 (en)	2015-04-02	2016-10-06	Intervet International B.V.	Antibodies to canine interleukin-4 receptor alpha
ES3029413T3 (en)	2015-04-02	2025-06-24	Ablynx Nv	Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
ES2876974T3 (es)	2015-04-07	2021-11-15	Novartis Ag	Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
EP3283108B1 (en)	2015-04-13	2020-10-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
US9778265B2 (en)	2015-04-16	2017-10-03	The United States Of America, As Represented By The Secretary Of The Navy	Charged peptide appendage to facilitate oriented protein covalent immobilization
US20180112006A1 (en)	2015-04-17	2018-04-26	The General Hospital Corporation	Agents, systems and methods for treating cancer
CN108473957B (zh)	2015-04-17	2024-07-16	诺华股份有限公司	改善嵌合抗原受体表达细胞的功效和扩增的方法
WO2016172583A1 (en)	2015-04-23	2016-10-27	Novartis Ag	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
TWI716405B (zh)	2015-05-07	2021-01-21	美商艾吉納斯公司	抗ox40抗體及其使用方法
EP3294334B1 (en)	2015-05-11	2020-07-08	The Johns Hopkins University	Autoimmune antibodies for use in inhibiting cancer cell growth
SI3294319T1 (sl)	2015-05-13	2024-09-30	Ablynx Nv	Polipeptidi, ki rekrutirajo celice T na osnovi reaktivnosti CD3
EP3611192B1 (en)	2015-05-13	2025-03-05	Ablynx N.V.	T cell recruiting polypeptides based on tcr alpha/beta reactivity
CN111234027A (zh)	2015-05-21	2020-06-05	哈普恩治疗公司	三特异性结合蛋白质及使用方法
WO2016191659A1 (en)	2015-05-28	2016-12-01	Bio-Rad Laboratories, Inc.	Affinity ligands and methods relating thereto
CN107849144B (zh)	2015-05-29	2021-09-17	艾吉纳斯公司	抗-ctla-4抗体及其使用方法
CA2982237A1 (en)	2015-06-05	2016-12-08	Novartis Ag	Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
EP3307777A4 (en)	2015-06-11	2019-02-13	Wuxi Biologics (Shanghai) Co. Ltd.	NOVEL ANTI-PD-L1 ANTIBODIES
WO2016207313A1 (en)	2015-06-24	2016-12-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and kits for detecting protein-protein interactions
JOP20200312A1 (ar)	2015-06-26	2017-06-16	Novartis Ag	الأجسام المضادة للعامل xi وطرق الاستخدام
MX390949B (es)	2015-07-17	2025-03-21	Univ Brussel Vrije	Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer.
JP7146632B2 (ja)	2015-07-21	2022-10-04	ノバルティスアーゲー	免疫細胞の有効性および増大を改善する方法
EP3878465A1 (en)	2015-07-29	2021-09-15	Novartis AG	Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da)	2015-07-29	2021-06-28	Immutep Sas	Kombinationsterapier omfattende antistofmolekyler mod lag-3
US20180222982A1 (en)	2015-07-29	2018-08-09	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
EP3328393B1 (en)	2015-07-31	2023-12-20	Centrose, Llc	Extracellular drug conjugates targeting cd20
GB2557123B (en)	2015-07-31	2021-11-03	Univ Minnesota	Modified cells and methods of therapy
KR102728071B1 (ko)	2015-08-03	2024-11-11	노파르티스 아게	Fgf21-연관 장애를 치료하는 방법
WO2017020291A1 (en)	2015-08-06	2017-02-09	Wuxi Biologics (Shanghai) Co. Ltd.	Novel anti-pd-l1 antibodies
ES2855998T3 (es)	2015-08-07	2021-09-27	Merck Patent Gmbh	Etiqueta transglutamina para bioconjugación específica de sitio eficiente
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
FI3334763T3 (fi)	2015-08-11	2024-10-30	Wuxi Biologics Ireland Ltd	Uusia pd-l1-vasta-aineita
ES2911015T3 (es)	2015-08-31	2022-05-17	Helixmith Co Ltd	Receptores quiméricos de antígeno anti-sialil Tn
HK1257840A1 (zh)	2015-09-01	2019-11-01	Agenus Inc.	抗-pd-1抗体及其使用方法
US11747346B2 (en)	2015-09-03	2023-09-05	Novartis Ag	Biomarkers predictive of cytokine release syndrome
MY186352A (en)	2015-09-09	2021-07-15	Novartis Ag	Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
RS61763B1 (sr)	2015-09-09	2021-05-31	Novartis Ag	Antitela koja vezuju timusni stromalni limfopoetin (tslp) i metode za korišćenje antitela
WO2017053469A2 (en)	2015-09-21	2017-03-30	Aptevo Research And Development Llc	Cd3 binding polypeptides
JP2018530574A (ja)	2015-10-07	2018-10-18	アレクシオンファーマシューティカルズ，インコーポレイテッド	患者の加齢黄斑変性を治療する方法
MA45819A (fr)	2015-10-09	2018-08-15	Sarepta Therapeutics Inc	Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
CN105238759B (zh) *	2015-10-14	2019-05-24	吉日木图	抗驼乳重链IgG3单克隆抗体、含有所述单克隆抗体的试纸及其应用
WO2017083515A2 (en)	2015-11-10	2017-05-18	Visterra, Inc.	Antibody molecule-drug conjugates and uses thereof
NO2768984T3 (da)	2015-11-12	2018-06-09
US20180327499A1 (en)	2015-11-13	2018-11-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti- nkg2d single domain antibodies and uses thereof
SG10201911035QA (en)	2015-11-18	2020-01-30	Merck Sharp & Dohme	Pd1 and/or lag3 binders
HK1254952A1 (zh)	2015-11-18	2019-08-02	Merck Sharp & Dohme Llc	Ctla4结合剂
HRP20231578T1 (hr)	2015-11-25	2024-03-15	Visterra, Inc.	Molekule protutijela na april i njihove uporabe
CA3006398A1 (en)	2015-11-27	2017-06-01	Ablynx Nv	Polypeptides inhibiting cd40l
SG10201912051TA (en)	2015-11-27	2020-02-27	Csl Ltd	Cd131 binding proteins and uses thereof
MA54648A (fr)	2015-12-04	2021-11-10	Boehringer Ingelheim Int	Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales
US11479755B2 (en)	2015-12-07	2022-10-25	2Seventy Bio, Inc.	T cell compositions
WO2017097889A1 (en)	2015-12-10	2017-06-15	Katholieke Universiteit Leuven	Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
MX2018007406A (es)	2015-12-16	2018-08-15	Merck Sharp & Dohme	Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
JP2019502695A (ja)	2015-12-17	2019-01-31	ノバルティスアーゲー	ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
EP3389712B1 (en)	2015-12-17	2024-04-10	Novartis AG	Antibody molecules to pd-1 and uses thereof
JP7008020B2 (ja)	2015-12-18	2022-01-25	インターベットインターナショナルベー．フェー．	ヒトおよびイヌｉｌ－４ｒアルファに対するイヌ化ヒト抗体
US11091556B2 (en)	2015-12-18	2021-08-17	Intervet Inc.	Caninized human antibodies to human IL-4R alpha
UY37030A (es)	2015-12-18	2017-07-31	Novartis Ag	Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
MA44140A (fr)	2015-12-22	2021-05-19	Dana Farber Cancer Inst Inc	Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
CN109153975A (zh)	2015-12-28	2019-01-04	诺华股份有限公司	制备嵌合抗原受体表达细胞的方法
CN116769054A (zh)	2016-02-05	2023-09-19	奥里尼斯生物科学私人有限公司	双特异性信号传导剂及其用途
SG11201805941WA (en)	2016-02-17	2018-09-27	Novartis Ag	Tgfbeta 2 antibodies
CA3016287A1 (en)	2016-03-04	2017-09-08	Novartis Ag	Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US11248057B2 (en)	2016-03-07	2022-02-15	Vib Vzw	CD20 binding single domain antibodies
JP7034489B2 (ja)	2016-03-15	2022-03-14	アイタブメッド（エイチケイ）リミテッド	多重特異性Ｆａｂ融合タンパクおよびその使用
WO2017158396A1 (en)	2016-03-16	2017-09-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EP3433615A1 (en)	2016-03-21	2019-01-30	Institut National de la Sante et de la Recherche Medicale (INSERM)	Methods for diagnosis and treatment of solar lentigo
US11291721B2 (en)	2016-03-21	2022-04-05	Marengo Therapeutics, Inc.	Multispecific and multifunctional molecules and uses thereof
RU2744959C2 (ru)	2016-03-23	2021-03-17	Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд	Новые анти-pd-l1 антитела
JP7069032B2 (ja)	2016-03-24	2022-05-17	ミレニアムファーマシューティカルズ，インコーポレイテッド	がん免疫治療における胃腸の免疫関連有害事象の治療方法
TW201735949A (zh)	2016-03-24	2017-10-16	千禧製藥公司	治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
EP3433274A1 (en)	2016-03-25	2019-01-30	Visterra, Inc.	Formulation of antibody molecules to dengue virus
WO2017176762A1 (en)	2016-04-06	2017-10-12	Nanotics, Llc	Particles comprising subparticles or nucleic acid scaffolds
US20190120838A1 (en)	2016-04-13	2019-04-25	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and kits for the rapid detection of the escherichia coli o25b-st131 clone
JP7125351B2 (ja)	2016-04-14	2022-08-24	２セブンティバイオインコーポレイテッド	サルベージキメラ抗原受容体システム
SI3443096T1 (sl)	2016-04-15	2023-07-31	Novartis Ag	Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev
WO2017181098A2 (en)	2016-04-15	2017-10-19	Visterra, Inc.	Antibody molecules to zika virus and uses thereof
CA3019588A1 (en)	2016-04-20	2017-10-26	Merck Sharp & Dohme Corp.	Cmv neutralizing antigen binding proteins
WO2017182605A1 (en)	2016-04-22	2017-10-26	Université Libre de Bruxelles	A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
US11243214B2 (en)	2016-04-22	2022-02-08	Université Libre de Bruxelles	Biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
JP7138567B2 (ja)	2016-04-27	2022-09-16	ノバルティスアーゲー	成長分化因子１５に対する抗体およびそれらの使用
PL3452507T3 (pl)	2016-05-02	2023-01-09	Prothena Biosciences Limited	Immunoterapia tau
WO2017191108A1 (en)	2016-05-02	2017-11-09	Ablynx Nv	Treatment of rsv infection
CN109563141A (zh)	2016-05-13	2019-04-02	奥里尼斯生物科学公司	对非细胞结构的治疗性靶向
MA55697A (fr)	2016-05-18	2022-02-23	Boehringer Ingelheim Int	Molécules d'anticorps pour le traitement du cancer
CN109641046B (zh)	2016-05-20	2023-11-07	哈普恩治疗公司	单链可变片段cd3结合蛋白质
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
BR112018073739A2 (pt)	2016-05-20	2019-02-26	Harpoon Therapeutics, Inc.	proteína de ligação de albumina sérica de domínio único
WO2017202962A1 (en)	2016-05-24	2017-11-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
MA45123A (fr)	2016-05-27	2019-04-10	Agenus Inc	Anticorps anti-tim-3 et leurs méthodes d'utilisation
JP2019517473A (ja)	2016-05-27	2019-06-24	アレクシオンファーマシューティカルズインコーポレイテッドＡｌｅｘｉｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	難治性全身型重症筋無力症の処置のための方法
EP3463482B1 (en)	2016-06-07	2021-10-06	The Brigham and Women's Hospital, Inc.	Methods relating to t peripheral helper cells in autoantibody-associated conditions
CN110381988A (zh)	2016-06-15	2019-10-25	诺华股份有限公司	使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
US11197902B2 (en)	2016-06-24	2021-12-14	Ig Biosciences Corporation	Prebiotic neutraceutical compositions and methods of treatment using the same
WO2018007442A1 (en)	2016-07-06	2018-01-11	Ablynx N.V.	Treatment of il-6r related diseases
CA3030099A1 (en)	2016-07-08	2018-01-11	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
BR112019000630A2 (pt)	2016-07-13	2019-07-09	Biogen Ma Inc	regimes de dosagem dos antagonistas de lingo-1 e usos para tratamento de distúrbios desmielinizante
CN120285179A (zh)	2016-07-15	2025-07-11	诺华股份有限公司	使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
WO2018017964A2 (en)	2016-07-21	2018-01-25	Emory University	Ebola virus antibodies and binding agents derived therefrom
IL264486B2 (en)	2016-07-28	2025-04-01	Novartis Ag	Combination therapies of chimeric antigen receptors and PD-1 inhibitors
NL2017267B1 (en)	2016-07-29	2018-02-01	Aduro Biotech Holdings Europe B V	Anti-pd-1 antibodies
SG11201900885VA (en)	2016-08-01	2019-02-27	Novartis Ag	Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
NL2017270B1 (en)	2016-08-02	2018-02-09	Aduro Biotech Holdings Europe B V	New anti-hCTLA-4 antibodies
KR102777127B1 (ko)	2016-08-02	2025-03-07	비스테라, 인크.	조작된 폴리펩티드 및 그의 용도
CA3032826A1 (en)	2016-08-03	2018-02-08	Nextcure, Inc.	Compositions and methods for modulating lair signal transduction
WO2018029182A1 (en)	2016-08-08	2018-02-15	Ablynx N.V.	Il-6r single variable domain antibodies for treatment of il-6r related diseases
EP3512880A1 (en)	2016-09-15	2019-07-24	Ablynx NV	Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
US11111313B2 (en)	2016-09-20	2021-09-07	WuXi Biologics Ireland Limited	Anti-PCSK9 antibodies
RU2759334C2 (ru)	2016-09-21	2021-11-12	Нексткьюр, Инк.	Антитела против siglec-15 и способы их применения
EP4360714A3 (en)	2016-09-21	2024-07-24	Nextcure, Inc.	Antibodies for siglec-15 and methods of use thereof
US11673971B2 (en)	2016-09-23	2023-06-13	Marengo Therapeutics, Inc.	Multispecific antibody molecules comprising lambda and kappa light chains
US20190248920A1 (en)	2016-09-23	2019-08-15	Csl Limited	Coagulation factor binding proteins and uses thereof
EP3519438A1 (en)	2016-09-30	2019-08-07	VHsquared Limited	Compositions
EP3523331A1 (en)	2016-10-07	2019-08-14	Novartis AG	Chimeric antigen receptors for the treatment of cancer
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
CA3037380A1 (en)	2016-10-11	2018-04-19	Agenus Inc.	Anti-lag-3 antibodies and methods of use thereof
US20190276524A1 (en)	2016-10-12	2019-09-12	Alexion Pharmaceuticals, Inc.	Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
CN110520530A (zh)	2016-10-18	2019-11-29	明尼苏达大学董事会	肿瘤浸润性淋巴细胞和治疗方法
ES2888904T3 (es)	2016-10-19	2022-01-10	Alexion Pharma Inc	Un método de cuantificación de C5a sin unir en una muestra
US11965884B2 (en)	2016-10-19	2024-04-23	Alexion Pharmaceuticals, Inc.	Method of quantitating unbound C5 in a sample
ES2978486T3 (es)	2016-10-21	2024-09-13	Ose Immunotherapeutics	Métodos para promover la respuesta de linfocitos T
US20200057046A1 (en)	2016-10-27	2020-02-20	Alexion Pharmaceuticals, Inc.	Assay for c5b-9 deposition in complement-associated disorders
US20190263926A1 (en)	2016-10-28	2019-08-29	Astute Medical, Inc.	Use of Antibodies to TIMP-2 for the Improvement of Renal Function
WO2018078083A1 (en)	2016-10-28	2018-05-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	New method for treating multiple myeloma
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20240005168A (ko)	2016-11-04	2024-01-11	2세븐티 바이오, 인코포레이티드	항-bcma car t 세포 조성물
KR102539159B1 (ko)	2016-11-07	2023-06-02	주식회사 뉴라클사이언스	서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
AU2017361846B2 (en)	2016-11-16	2024-08-22	Ablynx Nv	T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
EP3541833B1 (en)	2016-11-17	2024-01-24	2seventy bio, Inc.	Tgf beta signal convertor
US11773163B2 (en)	2016-11-21	2023-10-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the prophylactic treatment of metastases
JP6812551B2 (ja)	2016-11-23	2021-01-13	ハープーンセラピューティクス，インク．	前立腺特異的膜抗原結合タンパク質
JP7215997B2 (ja)	2016-11-23	2023-01-31	ハープーンセラピューティクス，インク．	前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
WO2018099968A1 (en)	2016-11-29	2018-06-07	Ablynx N.V.	Treatment of infection by respiratory syncytial virus (rsv)
US10759855B2 (en)	2016-12-02	2020-09-01	Rigel Pharmaceuticals, Inc.	Antigen binding molecules to TIGIT
EP3551047A1 (en)	2016-12-07	2019-10-16	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
FI3551660T3 (fi)	2016-12-07	2023-12-11	Agenus Inc	Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
EP3551225A1 (en)	2016-12-07	2019-10-16	Agenus Inc.	Antibodies and methods of use thereof
WO2018112237A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
JP7150723B2 (ja)	2016-12-14	2022-10-11	ビオラ・セラピューティクス・インコーポレイテッド	消化管疾病のインテグリン阻害薬による治療
EP4190318A1 (en)	2016-12-14	2023-06-07	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
WO2018112232A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
TW201834711A (zh)	2016-12-14	2018-10-01	美商寶珍那提公司	以tnf抑制劑治療胃腸道疾病
CA3045310A1 (en)	2016-12-14	2018-06-21	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CA3046023A1 (en)	2016-12-14	2018-06-21	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunosuppressant
CA3046019A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a tlr modulator
WO2018112235A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
WO2018112256A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
EP3360898A1 (en)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
MY201744A (en)	2016-12-23	2024-03-15	Visterra Inc	Binding polypeptides and methods of making the same
AU2017383232B2 (en)	2016-12-23	2024-09-12	Novartis Ag	Factor XI antibodies and methods of use
ES2988845T3 (es)	2017-01-09	2024-11-21	Onkosxcel Therapeutics Llc	Procedimientos predictivos y diagnósticos para cáncer de próstata
EP3571223B1 (en)	2017-01-18	2024-09-18	Visterra, Inc.	Antibody molecule-drug conjugates and uses thereof
SG10202109874VA (en)	2017-01-19	2021-10-28	Open Monoclonal Tech Inc	Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
EP4043485A1 (en)	2017-01-26	2022-08-17	Novartis AG	Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018141753A1 (en)	2017-01-31	2018-08-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating squamous cell carcinomas
EP3577133A1 (en)	2017-02-06	2019-12-11	Orionis Biosciences NV	Targeted chimeric proteins and uses thereof
JP6991246B2 (ja)	2017-02-08	2022-02-03	ノバルティスアーゲー	Ｆｇｆ２１模倣抗体及びその使用
US20200291089A1 (en)	2017-02-16	2020-09-17	Elstar Therapeutics, Inc.	Multifunctional molecules comprising a trimeric ligand and uses thereof
US11964002B2 (en)	2017-02-28	2024-04-23	Vib Vzw	Means and methods for oral protein delivery
US11535668B2 (en)	2017-02-28	2022-12-27	Harpoon Therapeutics, Inc.	Inducible monovalent antigen binding protein
US20200048359A1 (en)	2017-02-28	2020-02-13	Novartis Ag	Shp inhibitor compositions and uses for chimeric antigen receptor therapy
DE202018006693U1 (de)	2017-03-14	2022-03-08	Nanotag Biotechnologies Gmbh	Target-Detektion mit einem monovalenten Antikörper
CN110753702B (zh)	2017-03-15	2022-09-20	清华大学	抗trkb抗体
WO2018167283A1 (en)	2017-03-17	2018-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
CA3054837A1 (en)	2017-03-24	2018-09-27	Novartis Ag	Methods for preventing and treating heart disease
KR20190133198A (ko)	2017-03-27	2019-12-02	셀진 코포레이션	면역원성의 감소를 위한 방법 및 조성물
AU2018244922A1 (en)	2017-03-30	2019-09-12	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with live biotherapeutics
WO2018183934A1 (en)	2017-03-30	2018-10-04	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
WO2018183932A1 (en)	2017-03-30	2018-10-04	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
US11596670B2 (en)	2017-03-30	2023-03-07	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
US20210138213A1 (en)	2017-03-30	2021-05-13	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018187227A1 (en)	2017-04-03	2018-10-11	Concologie, Inc.	Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
WO2018185516A1 (en)	2017-04-05	2018-10-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
EP3610264A1 (en)	2017-04-13	2020-02-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
BR112019017241A2 (pt)	2017-04-13	2020-04-14	Agenus Inc	anticorpos anti-cd137 e métodos de uso dos mesmos
WO2018189403A1 (en)	2017-04-14	2018-10-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of cancer
US20200033347A1 (en)	2017-04-18	2020-01-30	Universite Libre De Bruxelles	Biomarkers And Targets For Proliferative Diseases
WO2018195034A1 (en)	2017-04-19	2018-10-25	Alexion Pharmaceuticals, Inc.	Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
AU2018256406A1 (en)	2017-04-19	2019-10-17	Marengo Therapeutics, Inc.	Multispecific molecules and uses thereof
JP2020517242A (ja)	2017-04-21	2020-06-18	スターテン・バイオテクノロジー・ベー・フェー	抗ＡｐｏＣ３抗体およびその使用方法
EP3615055A1 (en)	2017-04-28	2020-03-04	Novartis AG	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615566B1 (en)	2017-04-28	2023-12-20	Marengo Therapeutics, Inc.	Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
WO2018201051A1 (en)	2017-04-28	2018-11-01	Novartis Ag	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
TW202402800A (zh)	2017-05-01	2024-01-16	美商艾吉納斯公司	抗ｔｉｇｉｔ抗體類和使用彼等之方法
WO2018206734A1 (en)	2017-05-11	2018-11-15	Vib Vzw	Glycosylation of variable immunoglobulin domains
CA3063362A1 (en)	2017-05-12	2018-11-15	Harpoon Therapeutics, Inc.	Msln targeting trispecific proteins and methods of use
CA3063359A1 (en)	2017-05-12	2018-11-15	Harpoon Therapeutics, Inc.	Mesothelin binding proteins
KR20200006985A (ko)	2017-05-12	2020-01-21	오거스타 유니버시티 리서치 인스티튜트, 인크.	인간 알파 태아단백-특이적 t 세포 수용체 및 이의 용도
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها
US11225514B2 (en)	2017-05-30	2022-01-18	The Regents Of The University Of California	Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)
US11033636B2 (en)	2017-05-31	2021-06-15	Boehringer Ingelheim International Gmbh	Polypeptides antagonizing Wnt signaling in tumor cells
EP3630836A1 (en)	2017-05-31	2020-04-08	Elstar Therapeutics, Inc.	Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
IL270951B2 (en)	2017-06-02	2025-05-01	Merck Patent Gmbh	ADAMTS5, MMP13 and aggrecan-binding polypeptides
LT3630847T (lt)	2017-06-02	2024-12-10	Merck Patent Gmbh	Adamts surišantys imunoglobulinai
CN110997716B (zh)	2017-06-02	2024-03-15	埃博灵克斯股份有限公司	结合聚集蛋白聚糖的免疫球蛋白
EP3630822A1 (en)	2017-06-02	2020-04-08	Boehringer Ingelheim International GmbH	Anti-cancer combination therapy
KR102778120B1 (ko)	2017-06-02	2025-03-06	메르크 파텐트 게엠베하	Mmp13 결합성 면역글로불린
EP3415010A1 (en)	2017-06-13	2018-12-19	Agrosavfe Nv	Insect-controlling polypeptides and methods
GB201709379D0 (en)	2017-06-13	2017-07-26	Univ Leuven Kath	Humanised ADAMTS13 binding antibodies
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018236904A1 (en)	2017-06-19	2018-12-27	Surface Oncology, Inc.	Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
WO2018237173A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Antibody molecules to cd73 and uses thereof
EP3641812A1 (en)	2017-06-22	2020-04-29	Novartis AG	Antibody molecules to cd73 and uses thereof
EP3645563A4 (en)	2017-06-27	2021-03-17	Neuracle Science Co., Ltd	ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
AU2018292618A1 (en)	2017-06-27	2019-12-19	Novartis Ag	Dosage regimens for anti-TIM-3 antibodies and uses thereof
WO2019000223A1 (en)	2017-06-27	2019-01-03	Nanjing Legend Biotech Co., Ltd.	ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
JP2020525421A (ja)	2017-06-28	2020-08-27	ノバルティスアーゲー	尿失禁を予防及び治療するための方法
EP3645041A4 (en)	2017-06-28	2021-03-17	The Rockefeller University	AGONISTIC ANTIBODY-ANTIBODY-ACTIVE INGREDIENT CONJUGATES AGAINST MERTK AND THEIR USES
WO2019006418A2 (en)	2017-06-30	2019-01-03	Intima Bioscience, Inc.	ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
BR112019028269A2 (pt)	2017-07-11	2020-07-14	Alexion Pharmaceuticals, Inc.	polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
EP3652209A2 (en)	2017-07-11	2020-05-20	Compass Therapeutics LLC	Agonist antibodies that bind human cd137 and uses thereof
WO2019012030A1 (en)	2017-07-13	2019-01-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
CA3070253A1 (en)	2017-07-19	2019-01-24	Vib Vzw	Serum albumin binding agents
EP3431496A1 (en)	2017-07-19	2019-01-23	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Anti- isoasp7 amyloid beta antibodies and uses thereof
KR20250025039A (ko)	2017-07-20	2025-02-20	노파르티스 아게	항-lag-3 항체의 투여 요법 및 그의 용도
WO2019016784A1 (en)	2017-07-21	2019-01-24	Universidade De Coimbra	ANTI-NUCLEOLIN ANTIBODIES
WO2019020480A1 (en)	2017-07-24	2019-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
ES2965486T3 (es)	2017-07-27	2024-04-15	Alexion Pharma Inc	Formulaciones de anticuerpos anti-C5 de alta concentración
JP2020529605A (ja)	2017-08-01	2020-10-08	コンパスセラピューティクスリミテッドライアビリティカンパニー	濾過およびクロマトグラフィ用ポッドならびにその使用方法
US20200306516A1 (en)	2017-08-14	2020-10-01	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
WO2019035938A1 (en)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3684811A2 (en)	2017-08-17	2020-07-29	Massachusetts Institute of Technology	Multiple specificity binders of cxc chemokines and uses thereof
JP2020532991A (ja)	2017-09-07	2020-11-19	オーガスタユニバーシティリサーチインスティテュート，インコーポレーテッド	プログラム細胞死タンパク質１に対する抗体
JP7733443B2 (ja)	2017-09-11	2025-09-03	モナシュユニバーシティー	ヒトトロンビン受容体ｐａｒ４に対する結合タンパク質
JP7330174B2 (ja)	2017-09-20	2023-08-21	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	オートファジーをモジュレーションするための方法及び医薬組成物
MY205689A (en)	2017-10-02	2024-11-06	Visterra Inc	Antibody molecules to cd138 and uses thereof
ES2759622T3 (es)	2017-10-02	2020-05-11	Certest Biotec S L	Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
EP3694552A1 (en)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anti-lap antibodies and uses thereof
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
UA129446C2 (uk)	2017-10-13	2025-04-30	Гарпун Терап'Ютікс, Інк.	Триспецифічні білки і способи їх застосування
WO2019073080A1 (en)	2017-10-13	2019-04-18	Ose Immunotherapeutics	ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF
CN111247165B (zh)	2017-10-18	2023-11-10	Csl有限公司	人血清白蛋白变体及其应用
WO2019077132A1 (en)	2017-10-19	2019-04-25	Debiopharm International S.A.	COMBINATION PRODUCT FOR THE TREATMENT OF CANCER
US20210040205A1 (en)	2017-10-25	2021-02-11	Novartis Ag	Antibodies targeting cd32b and methods of use thereof
MX2020004229A (es)	2017-10-25	2020-07-22	Novartis Ag	Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
KR20200070355A (ko)	2017-10-26	2020-06-17	알렉시온 파마슈티칼스, 인코포레이티드	발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
WO2019089753A2 (en)	2017-10-31	2019-05-09	Compass Therapeutics Llc	Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019086548A1 (en)	2017-10-31	2019-05-09	Vib Vzw	Novel antigen-binding chimeric proteins and methods and uses thereof
BR112020008514A2 (pt)	2017-10-31	2020-10-20	Staten Biotechnology B.V.	anticorpos anti-apoc3 e métodos de uso dos mesmos
US20210179709A1 (en)	2017-10-31	2021-06-17	Novartis Ag	Anti-car compositions and methods
US20190160102A1 (en)	2017-11-03	2019-05-30	Rubius Therapeutics, Inc.	Compositions and methods related to therapeutic cell systems for tumor growth inhibition
AU2018368731A1 (en)	2017-11-16	2020-05-14	Novartis Ag	Combination therapies
US11851497B2 (en)	2017-11-20	2023-12-26	Compass Therapeutics Llc	CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
PL3717011T3 (pl)	2017-11-29	2023-03-27	Csl Limited	Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu
WO2019106126A1 (en)	2017-12-01	2019-06-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Mdm2 modulators for the diagnosis and treatment of liposarcoma
CN112218943B (zh)	2017-12-05	2025-10-21	塞利亚德股份公司	减少表达基于nkg2d的受体的免疫细胞的杀伤剂
CN112236514A (zh)	2017-12-05	2021-01-15	塞利亚德股份公司	改善细胞过继转移的持久性的组合物和方法
JP7348899B2 (ja)	2017-12-08	2023-09-21	マレンゴ・セラピューティクス，インコーポレーテッド	多重特異性分子及びその使用
WO2019121872A1 (en)	2017-12-20	2019-06-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of liver cancer
WO2019129054A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	三链抗体、其制备方法及其用途
CN109970857B (zh)	2017-12-27	2022-09-30	信达生物制药(苏州)有限公司	抗pd-l1抗体及其用途
WO2019129136A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	抗pd-l1抗体及其用途
CN109970856B (zh)	2017-12-27	2022-08-23	信达生物制药(苏州)有限公司	抗lag-3抗体及其用途
WO2019129137A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	抗lag-3抗体及其用途
CN117050184A (zh)	2017-12-28	2023-11-14	南京传奇生物科技有限公司	针对tigit的单域抗体和其变体
CN108218990B (zh)	2017-12-29	2021-03-02	南京优迈生物科技有限公司	分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
EP3737692A4 (en)	2018-01-09	2021-09-29	Elstar Therapeutics, Inc.	CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US20190330591A1 (en)	2018-01-10	2019-10-31	Rubius Therapeutics, Inc.	Amplifiable rnas for therapeutic cell systems
JP7366908B2 (ja)	2018-01-15	2023-10-23	ナンジンレジェンドバイオテックカンパニー，リミテッド	Ｐｄ－１に対する単一ドメイン抗体及びその変異体
EP3740231A4 (en)	2018-01-18	2022-03-23	California Institute of Technology	PROGRAMMABLE PROTEIN CIRCUITS IN LIVING CELLS
US11965191B2 (en)	2018-01-18	2024-04-23	California Institute Of Technology	Programmable protein circuits in living cells
KR20200112913A (ko)	2018-01-23	2020-10-05	넥스트큐어 인코포레이티드	B7-h4 항체 및 그 사용 방법
JP2021510594A (ja)	2018-01-25	2021-04-30	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	臓器の虚血再灌流傷害を予防する方法における使用のためのｉｌ−３３のアンタゴニスト
WO2019148089A1 (en)	2018-01-26	2019-08-01	Orionis Biosciences Inc.	Xcr1 binding agents and uses thereof
CA3090249A1 (en)	2018-01-31	2019-08-08	Novartis Ag	Combination therapy using a chimeric antigen receptor
US12180285B2 (en)	2018-02-01	2024-12-31	Memorial Sloan Kettering Cancer Center	Antibodies to galectin-3 and methods of use thereof
WO2019151865A1 (en)	2018-02-05	2019-08-08	Stichting Vu	Inverse agonistic anti-us28 antibodies
MX2020008208A (es)	2018-02-05	2020-11-09	Orionis Biosciences Inc	Agentes de unión a fibroblastos y uso de estos.
MY204220A (en)	2018-02-06	2024-08-16	Ablynx Nv	Methods of treating initial episode of ttp with immunoglobulin single variable domains
WO2019157191A1 (en)	2018-02-07	2019-08-15	Georgia Tech Research Corporation	Methods for multiplexed cell isolation using dna gates
WO2019156566A1 (en)	2018-02-12	2019-08-15	Umc Utrecht Holding B.V.	Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019155041A1 (en)	2018-02-12	2019-08-15	Vib Vzw	Gβγ COMPLEX ANTIBODIES AND USES THEREOF
EP3752194A4 (en)	2018-02-13	2022-03-16	Checkmate Pharmaceuticals, Inc.	COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
WO2019158512A1 (en)	2018-02-13	2019-08-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the prognosis and the treatment of glioblastoma
EP3758742A1 (en)	2018-03-01	2021-01-06	Vrije Universiteit Brussel	Human pd-l1-binding immunoglobulins
WO2019169229A1 (en)	2018-03-01	2019-09-06	Nextcure, Inc.	Klrg1 binding compositions and methods of use thereof
NL2020520B1 (en)	2018-03-02	2019-09-12	Labo Bio Medical Invest B V	Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
AU2019233603B2 (en)	2018-03-13	2025-06-26	Smivet B.V.	Single domain antibodies binding to tetanus neurotoxin
US20210009711A1 (en)	2018-03-14	2021-01-14	Elstar Therapeutics, Inc.	Multifunctional molecules and uses thereof
MX394121B (es)	2018-03-14	2025-03-24	Surface Oncology Inc	Anticuerpos que se unen a cd39 y sus usos
US12152073B2 (en)	2018-03-14	2024-11-26	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
US11661452B2 (en)	2018-03-20	2023-05-30	WuXi Biologics Ireland Limited	Anti-lag-3 antibody polypeptide
EP3768725A4 (en)	2018-03-20	2021-06-02	Wuxi Biologics Ireland Limited	NEW ANTI-TIM-3 ANTIBODIES
BR112020018918A2 (pt)	2018-03-22	2021-01-05	Surface Oncology, Inc.	Anticorpos anti-il-27 e usos dos mesmos
KR102879500B1 (ko)	2018-03-23	2025-10-31	유니베르시테 리브레 드 브룩크젤즈	Wnt 시그널링 작용제 분자
WO2019178645A1 (en)	2018-03-23	2019-09-26	Csl Limited	Method of treating asthma
CN112384236A (zh)	2018-03-27	2021-02-19	Umc乌得勒支控股有限公司	用于治疗微血管血栓形成的靶向溶栓
WO2019184909A1 (zh)	2018-03-27	2019-10-03	信达生物制药(苏州)有限公司	新型抗体分子、其制备方法及其用途
US20210047696A1 (en)	2018-03-28	2021-02-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
AU2019241350B2 (en)	2018-03-30	2025-10-02	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies against LAG-3 and uses thereof
WO2019193375A1 (en)	2018-04-04	2019-10-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of fzd7 inhibitors for the treatment of retinal neovascularization
EP3775218A1 (en)	2018-04-09	2021-02-17	Checkmate Pharmaceuticals	Packaging oligonucleotides into virus-like particles
WO2019200357A1 (en)	2018-04-12	2019-10-17	Surface Oncology, Inc.	Biomarker for cd47 targeting therapeutics and uses therefor
US20210147547A1 (en)	2018-04-13	2021-05-20	Novartis Ag	Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019197683A1 (en)	2018-04-13	2019-10-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
WO2019207030A1 (en)	2018-04-26	2019-10-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
US20210047405A1 (en)	2018-04-27	2021-02-18	Novartis Ag	Car t cell therapies with enhanced efficacy
US12048745B2 (en)	2018-05-01	2024-07-30	Augusta University Research Institute, Inc.	Methods for detecting and reversing immune therapy resistance
WO2019211370A1 (en)	2018-05-03	2019-11-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
WO2019211369A1 (en)	2018-05-03	2019-11-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
AU2019265888A1 (en)	2018-05-10	2020-11-26	Neuracle Science Co., Ltd.	Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
US20190345261A1 (en)	2018-05-10	2019-11-14	Sensei Biotherapeutics, Inc.	Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
WO2019222283A1 (en)	2018-05-14	2019-11-21	Harpoon Therapeutics, Inc.	Binding moiety for conditional activation of immunoglobulin molecules
EP3569618A1 (en)	2018-05-19	2019-11-20	Boehringer Ingelheim International GmbH	Antagonizing cd73 antibody
WO2019226658A1 (en)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Multispecific antigen-binding compositions and methods of use
AU2019272575A1 (en)	2018-05-21	2020-12-10	Compass Therapeutics Llc	Compositions and methods for enhancing the killing of target cells by NK cells
WO2019226050A2 (en)	2018-05-24	2019-11-28	Wageningen Universiteit	Novel viral anti-infective reagents
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en)	2018-05-31	2021-07-15	Novartis Ag	Antibody molecules to cd73 and uses thereof
ES2996257T3 (en)	2018-05-31	2025-02-12	Alexion Pharma Inc	Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
TWI848951B (zh)	2018-06-01	2024-07-21	瑞士商諾華公司	針對ｂｃｍａ之結合分子及其用途
EP3802603A1 (en)	2018-06-04	2021-04-14	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
WO2019234099A1 (en)	2018-06-06	2019-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en)	2018-06-08	2019-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
TWI848953B (zh)	2018-06-09	2024-07-21	德商百靈佳殷格翰國際股份有限公司	針對癌症治療之多特異性結合蛋白
WO2019241315A1 (en)	2018-06-12	2019-12-19	Obsidian Therapeutics, Inc.	Pde5 derived regulatory constructs and methods of use in immunotherapy
AU2019284911A1 (en)	2018-06-13	2020-12-17	Novartis Ag	BCMA chimeric antigen receptors and uses thereof
BR112020025439A2 (pt)	2018-06-14	2021-03-16	Bluebird Bio, Inc.	Receptores de antígenos quiméricos cd79a
KR20210022004A (ko)	2018-06-18	2021-03-02	안위타 바이오사이언시스, 인코포레이티드	항-메소텔린 작제물 및 이의 용도
US20210238268A1 (en)	2018-06-19	2021-08-05	Atarga, Llc	Antibody molecules to complement component 5 and uses thereof
US20230041197A1 (en)	2018-06-20	2023-02-09	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease or condition in a tissue originating from the endoderm
WO2020006266A1 (en)	2018-06-28	2020-01-02	Alexion Pharmaceuticals, Inc.	Methods of producing anti-c5 antibodies
MX2020013923A (es)	2018-06-29	2021-03-29	Apitbio Inc	Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
WO2020001526A1 (zh)	2018-06-29	2020-01-02	苏州智核生物医药科技有限公司	Pd-l1结合多肽及其用途
AU2019297451A1 (en)	2018-07-03	2021-01-28	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
CN118147029A (zh)	2018-07-11	2024-06-07	阿克蒂姆治疗有限公司	工程化的免疫刺激性细菌菌株及其用途
TW202019474A (zh)	2018-07-11	2020-06-01	美商西建公司	抗bcma嵌合抗原受體之用途
WO2020016160A1 (en)	2018-07-16	2020-01-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method to treat neurological diseases
EP3823672A1 (en)	2018-07-19	2021-05-26	Institut National de la Santé et de la Recherche Médicale (INSERM)	Combination for treating cancer
CN118994395A (zh)	2018-07-20	2024-11-22	皮埃尔法布雷医药公司	Vista受体
WO2020021465A1 (en)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Method of treatment of neuroendocrine tumors
ES2738926A1 (es)	2018-07-26	2020-01-27	Univ Zaragoza	Granulisina, metodo de obtencion y usos
US20210186880A1 (en)	2018-08-03	2021-06-24	Brown University	Oral formulations with increased uptake
EP3833442A2 (en)	2018-08-09	2021-06-16	Compass Therapeutics LLC	Antibodies that bind cd277 and uses thereof
EP3833443A1 (en)	2018-08-09	2021-06-16	Compass Therapeutics LLC	Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (en)	2018-08-09	2020-02-13	Compass Therapeutics Llc	Antibodies that bind cd277 and uses thereof
US12391957B2 (en)	2018-08-17	2025-08-19	Icahn School Of Medicine At Mount Sinai	Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
US11453893B2 (en)	2018-08-30	2022-09-27	California Institute Of Technology	RNA-based delivery systems with levels of control
US11542305B2 (en)	2018-08-31	2023-01-03	California Institute Of Technology	Synthetic protein circuits detecting signal transducer activity
ES3042082T3 (en)	2018-08-31	2025-11-18	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en)	2018-08-31	2020-03-05	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
EP3848397A4 (en)	2018-09-04	2022-07-20	Nanjing Umab-Biopharma Co., Ltd.	Fusion protein and its application in preparing medicine for treating tumor and/or viral infection
GB201814451D0 (en)	2018-09-05	2018-10-17	Valerie Nicholas Carl Kristoffer	Methods
GB2576914A (en)	2018-09-06	2020-03-11	Kymab Ltd	Antigen-binding molecules comprising unpaired variable domains produced in mammals
EP3847196A4 (en)	2018-09-07	2023-01-04	ITabMed (HK) Limited	BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN113195516B (zh) *	2018-09-11	2025-07-15	纳诺泰克生物技术公司	由特异性结合物识别的表位标签
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
US12473357B2 (en)	2018-09-25	2025-11-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of antagonists of Th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
EP3856771A4 (en)	2018-09-25	2022-06-29	Harpoon Therapeutics, Inc.	Dll3 binding proteins and methods of use
CN113164777B (zh)	2018-09-27	2024-12-13	马伦戈治疗公司	Csf1r/ccr2多特异性抗体
AU2019346335B2 (en)	2018-09-28	2024-07-25	Massachusetts Institute Of Technology	Collagen-localized immunomodulatory molecules and methods thereof
WO2020070062A1 (en)	2018-10-01	2020-04-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
EP3860713A2 (en)	2018-10-03	2021-08-11	Staten Biotechnology B.V.	Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
EP3860653A1 (en)	2018-10-05	2021-08-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and systems for controlling the agonistic properties of antibody variable domains by light
WO2020076969A2 (en)	2018-10-10	2020-04-16	Tilos Therapeutics, Inc.	Anti-lap antibody variants and uses thereof
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
WO2020080941A1 (en)	2018-10-16	2020-04-23	Umc Utrecht Holding B.V.	Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2020086742A1 (en)	2018-10-24	2020-04-30	Obsidian Therapeutics, Inc.	Er tunable protein regulation
US12240893B2 (en)	2018-10-30	2025-03-04	Alexion Pharmaceuticals, Inc.	Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
US20220000893A1 (en)	2018-10-31	2022-01-06	\|Nserm (Institut National De La Santé Et De La Recherche Médicale)	Method for treating t-helper type 2 mediated disease
US12410225B2 (en)	2018-11-08	2025-09-09	Orionis Biosciences, Inc	Modulation of dendritic cell lineages
MX2021005594A (es)	2018-11-13	2021-10-22	Compass Therapeutics Llc	Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
GB201818477D0 (en)	2018-11-13	2018-12-26	Emstopa Ltd	Tissue plasminogen activator antibodies and method of use thereof
WO2020118293A2 (en)	2018-12-07	2020-06-11	Georgia Tech Research Corporation	Antibodies that bind to natively folded myocilin
MA54469A (fr)	2018-12-13	2021-10-20	Surface Oncology Inc	Anticorps anti-il-27 et leurs utilisations
WO2020120644A1 (en)	2018-12-13	2020-06-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	New anti tau svqivykpv epitope single domain antibody
JP2022513255A (ja)	2018-12-20	2022-02-07	ノバルティスアーゲー	ＨＤＭ２－ｐ５３相互作用阻害剤とＢＣＬ２阻害剤との組み合わせ及び癌を処置するためのその使用
KR20210107062A (ko)	2018-12-21	2021-08-31	오제 이뮈노테라프틱스	이작용성 항-PD-1/SIRPα 분자
CA3123338A1 (en)	2018-12-21	2020-06-25	Ose Immunotherapeutics	Bifunctional anti-pd-1/il-7 molecule
WO2020130838A2 (en)	2018-12-21	2020-06-25	Qvq Holding B.V.	Antibodies for preventing or treating candidiasis
CA3122899A1 (en)	2018-12-21	2020-06-25	Ose Immunotherapeutics	Bifunctional molecule directed against human pd-1
JP2022515960A (ja)	2019-01-02	2022-02-24	ニューラクルサイエンスカンパニーリミテッド	抗配列類似性１９を持つファミリー、メンバーａ５抗体及びその使用方法
KR20220008253A (ko)	2019-01-03	2022-01-20	엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름)	암을 앓는 대상에서 cd8+ t 세포 의존성 면역 반응을 향상시키기 위한 방법 및 약학적 조성물
EP3908602A1 (en)	2019-01-07	2021-11-17	Bactolife ApS	Pathogen binding proteins
EP3908653A4 (en)	2019-01-10	2022-11-02	California Institute of Technology	A synthetic system for tunable thresholding of protein signals
JP7645185B2 (ja)	2019-01-15	2025-03-13	アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル	変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用
WO2020148349A1 (en)	2019-01-16	2020-07-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Variants of erythroferrone and their use
US20220111047A1 (en)	2019-01-16	2022-04-14	Compass Therapeutics Llc	Formulations of antibodies that bind human cd137 and uses thereof
TWI756621B (zh)	2019-01-25	2022-03-01	大陸商信達生物製藥（蘇州）有限公司	新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
GB201901608D0 (en)	2019-02-06	2019-03-27	Vib Vzw	Vaccine adjuvant conjugates
WO2020165374A1 (en)	2019-02-14	2020-08-20	Ose Immunotherapeutics	Bifunctional molecule comprising il-15ra
US10871640B2 (en)	2019-02-15	2020-12-22	Perkinelmer Cellular Technologies Germany Gmbh	Methods and systems for automated imaging of three-dimensional objects
CA3129317A1 (en)	2019-02-15	2020-08-20	Integral Molecular, Inc.	Antibodies comprising a common light chain and uses thereof
KR20210128443A (ko)	2019-02-15	2021-10-26	인테그럴 몰큘러 인코포레이티드	클라우딘 6 항체 및 이의 용도
CA3131016A1 (en)	2019-02-21	2020-08-27	Andreas Loew	Multifunctional molecules that bind to calreticulin and uses thereof
CN119661722A (zh)	2019-02-21	2025-03-21	马伦戈治疗公司	结合t细胞相关癌细胞的多功能分子及其用途
WO2020169707A1 (en)	2019-02-21	2020-08-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Foxo1 inhibitor for use in the treatment of latent virus infection
GB2598218B (en)	2019-02-21	2024-05-08	Marengo Therapeutics Inc	Anti-TCR antibody molecules and uses thereof
WO2020172598A1 (en)	2019-02-21	2020-08-27	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
EP3927747A1 (en)	2019-02-21	2021-12-29	Marengo Therapeutics, Inc.	Antibody molecules that bind to nkp30 and uses thereof
US20220088075A1 (en)	2019-02-22	2022-03-24	The Trustees Of The University Of Pennsylvania	Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
ES2978570T3 (es)	2019-02-26	2024-09-16	Inspirna Inc	Anticuerpos anti-MERTK de alta afinidad y sus usos
EP3930757A1 (en)	2019-03-01	2022-01-05	President And Fellows Of Harvard College	Methods and compositions for protein delivery
EP3935084B1 (en)	2019-03-08	2024-06-12	LinXis B.V.	Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
KR20210149251A (ko)	2019-03-08	2021-12-08	옵시디안 테라퓨틱스, 인크.	조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
WO2020193740A1 (en)	2019-03-28	2020-10-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	New strategy for treating pancreatic cancer
WO2020198731A2 (en)	2019-03-28	2020-10-01	Danisco Us Inc	Engineered antibodies
PH12021552414A1 (en)	2019-03-29	2022-07-25	Atarga Llc	Anti fgf23 antibody
US12291562B2 (en)	2019-04-01	2025-05-06	Rush University Medical Center	Reagents and assays using modified integrin domains
WO2020205409A1 (en)	2019-04-03	2020-10-08	President And Fellows Of Harvard College	Ionic liquids for drug delivery
EP3947472A4 (en)	2019-04-04	2023-02-22	Vanderbilt University	THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF LUNG CANCER
WO2020208082A1 (en)	2019-04-09	2020-10-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating cmv related diseases
WO2020210678A1 (en)	2019-04-12	2020-10-15	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
SG11202111980QA (en)	2019-04-29	2021-11-29	Confo Therapeutics N V	Screening methods and assays for use with transmembrane proteins, in particular with gpcrs
EP3962599A1 (en)	2019-04-30	2022-03-09	Vib Vzw	Cystic fibrosis transmembrane conductance regulator stabilizing agents
US20200363400A1 (en)	2019-05-13	2020-11-19	Regeneron Pharmaceuticals, Inc.	Competitive Ligand Binding Assays
US12146160B2 (en)	2019-05-14	2024-11-19	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Regulatory T cells targeted by lymphotoxin alpha blocking agent and uses thereof
KR20220008866A (ko)	2019-05-14	2022-01-21	하푼 테라퓨틱스, 인크.	EpCAM 결합 단백질 및 사용 방법
US20220227859A1 (en)	2019-05-16	2022-07-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method to treat type 2 inflammation or mast-cell dependent disease
CA3140142A1 (en)	2019-05-21	2020-11-26	Novartis Ag	Trispecific binding molecules against bcma and uses thereof
US12037378B2 (en)	2019-05-21	2024-07-16	Novartis Ag	Variant CD58 domains and uses thereof
BR112021023048A2 (pt)	2019-05-21	2022-04-19	Novartis Ag	Moléculas de ligação a cd19 e usos das mesmas
CN114206935B (zh)	2019-05-24	2024-01-12	三优生物医药(上海)有限公司	新型cldn18.2结合分子
US20220220197A1 (en)	2019-05-28	2022-07-14	Vib Vzw	Cancer Treatment by Targeting Plexins in the Immune Compartment
WO2020239934A1 (en)	2019-05-28	2020-12-03	Vib Vzw	Cd8+ t-cells lacking plexins and their application in cancer treatment
GB2584441A (en)	2019-06-03	2020-12-09	Fenomark Diagnostics Ab	Medical uses, methods and uses
JP2022535553A (ja)	2019-06-04	2022-08-09	シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド	抗ｃｅａｃａｍ５モノクローナル抗体、その作製方法およびその使用
EP3983437A1 (en)	2019-06-12	2022-04-20	Novartis AG	Natriuretic peptide receptor 1 antibodies and methods of use
US12338291B2 (en)	2019-06-17	2025-06-24	Visterra, Inc.	Humanized antibody molecules to CD138 and uses thereof
JP7685957B2 (ja)	2019-06-20	2025-05-30	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	プロテアーゼネキシン－１に対する立体構造的な単一ドメイン抗体及びその使用
MX2021015762A (es)	2019-06-21	2022-04-18	Sorriso Pharmaceuticals Inc	Composiciones.
EP3986931A1 (en)	2019-06-21	2022-04-27	Sorriso Pharmaceuticals, Inc.	Polypeptides
AU2020294980A1 (en)	2019-06-21	2022-02-17	Sorriso Pharmaceuticals, Inc.	Polypeptides
EP3990491A1 (en)	2019-06-26	2022-05-04	Massachusetts Institute of Technology	Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
CN114466863A (zh)	2019-07-01	2022-05-10	苏州康宁杰瑞生物科技有限公司	百日咳毒素结合蛋白
WO2021001539A1 (en)	2019-07-04	2021-01-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	New strategy to detect and treat eosinophilic fasciitis
CA3145345A1 (en)	2019-07-15	2021-01-21	Intervet International B.V.	Caninized antibodies against canine ctla-4
PH12022550165A1 (en)	2019-07-26	2023-05-08	Visterra Inc	Interleukin-2 agents and uses thereof
WO2021025556A1 (en)	2019-08-05	2021-02-11	Stichting Vu	Identification and elimination of hcmv-infected cells
PH12022550460A1 (en)	2019-08-30	2023-02-27	Agenus Inc	Anti-cd96 antibodies and methods of use thereof
CN114616250B (zh)	2019-09-04	2024-11-08	豪夫迈·罗氏有限公司	Cd8结合剂及其用途
WO2021044012A1 (en)	2019-09-05	2021-03-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method of treatment and pronostic of acute myeloid leukemia
US20220348937A1 (en)	2019-09-06	2022-11-03	Obsidian Therapeutics, Inc.	Compositions and methods for dhfr tunable protein regulation
JP2022548484A (ja)	2019-09-16	2022-11-21	サーフィスオンコロジーインコーポレイテッド	抗ｃｄ３９抗体の組成物及び方法
US20220348651A1 (en)	2019-09-18	2022-11-03	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
TW202521984A (zh)	2019-09-25	2025-06-01	美商表面腫瘤學有限責任公司	抗ｉｌ－２７抗體及其用途
TW202126295A (zh)	2019-09-27	2021-07-16	大陸商江蘇挪貝肽醫藥科技有限公司	一種治療心境障礙的方法
US20220290151A1 (en)	2019-09-27	2022-09-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of müllerian inhibiting substance inhibitors for treating cancer
TWI878355B (zh)	2019-10-02	2025-04-01	德商百靈佳殷格翰國際股份有限公司	用於癌症治療之多重專一性結合蛋白
EP3799881A1 (en)	2019-10-04	2021-04-07	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Single domain antibodies specifically binding globo - series glycans
CN114786679A (zh)	2019-10-21	2022-07-22	诺华股份有限公司	具有维奈托克和tim-3抑制剂的组合疗法
WO2021078786A1 (en)	2019-10-21	2021-04-29	Vib Vzw	Nanodisc-specific antigen-binding chimeric proteins
CN114786680A (zh)	2019-10-21	2022-07-22	诺华股份有限公司	Tim-3抑制剂及其用途
US11459389B2 (en)	2019-10-24	2022-10-04	Massachusetts Institute Of Technology	Monoclonal antibodies that bind human CD161
WO2021086948A1 (en)	2019-10-28	2021-05-06	Georgia Tech Research Corporation	Mrna-encoded antibodies for contraception
US20240148901A1 (en)	2019-10-28	2024-05-09	Georgia Tech Research Corporation	Compositions and methods for prophylaxis of hiv
US20210128619A1 (en)	2019-11-05	2021-05-06	Celgene Corporation	Uses of anti-bcma chimeric antigen receptors
BR112022009087A2 (pt)	2019-11-11	2022-07-26	Ibi Ag Innovative Bio Insecticides Ltd	Nanocorpos para controle de insetos e usos dos mesmos
EP4058578A2 (en)	2019-11-12	2022-09-21	Actym Therapeutics, Inc.	Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
JP2023503899A (ja)	2019-11-22	2023-02-01	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	薬物送達のためのイオン液体
CA3163104A1 (en)	2019-11-26	2021-06-03	Novartis Ag	Chimeric antigen receptors and uses thereof
WO2021105391A1 (en)	2019-11-27	2021-06-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination comprising nupr1 inhibitors to treat cancer
WO2021105438A1 (en)	2019-11-27	2021-06-03	Vib Vzw	Positive allosteric modulators of the calcium-sensing receptor
WO2021105384A1 (en)	2019-11-27	2021-06-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Targeting the nls region of nupr1 protein to treat cancer
EP4069372A1 (en)	2019-12-05	2022-10-12	Ose Immunotherapeutics	Anti-clec-1a antibodies and antigen-binding fragment thereof
US11897950B2 (en)	2019-12-06	2024-02-13	Augusta University Research Institute, Inc.	Osteopontin monoclonal antibodies
CN114981300B (zh)	2019-12-06	2025-10-31	艾伯霖克斯公司	包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
CA3163764A1 (en)	2019-12-06	2021-06-10	Ablynx Nv	Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
AU2020400938A1 (en)	2019-12-09	2022-07-28	Ablynx Nv	Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
US20230040928A1 (en)	2019-12-09	2023-02-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies having specificity to her4 and uses thereof
GB201918279D0 (en)	2019-12-12	2020-01-29	Vib Vzw	Glycosylated single chain immunoglobulin domains
TW202136287A (zh)	2019-12-17	2021-10-01	法商Ｏｓｅ免疫治療公司	包含il-7變體之雙官能分子
JP2023508023A (ja)	2019-12-20	2023-02-28	ハドソンインスティチュートオブメディカルリサーチ	Ｃｘｃｌ１０結合タンパク質及びその使用
AU2020407124A1 (en)	2019-12-20	2022-07-21	Momenta Pharmaceuticals, Inc.	Antibodies against integrin alpha 11 beta 1
EP4077372A1 (en)	2019-12-20	2022-10-26	Vib Vzw	Nanobody exchange chromatography
MX2022007759A (es)	2019-12-20	2022-07-19	Novartis Ag	Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
WO2021138407A2 (en)	2020-01-03	2021-07-08	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to cd33 and uses thereof
GB2609554B (en)	2020-01-03	2025-08-20	Marengo Therapeutics Inc	Anti-TCR antibody molecules and uses thereof
TWI845803B (zh)	2020-01-06	2024-06-21	美商法西尼克斯股份有限公司	抗ｃｃｒ８抗體及其用途
WO2021140205A1 (en)	2020-01-10	2021-07-15	Confo Therapeutics N.V.	Methods for generating antibodies and antibody fragments and libraries comprising same
TWI869528B (zh)	2020-01-13	2025-01-11	美商威特拉公司	C5ar1抗體分子及其用途
EP4090335A1 (en)	2020-01-17	2022-11-23	Novartis AG	Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
MX2022008845A (es)	2020-01-17	2022-08-10	Univ Gent	Anticuerpos de dominio unico de inmunoglobulina para la entrega de vacunas a traves de la mucosa.
WO2021156490A2 (en)	2020-02-06	2021-08-12	Vib Vzw	Corona virus binders
EP4104187A1 (en)	2020-02-14	2022-12-21	Novartis AG	Method of predicting response to chimeric antigen receptor therapy
IL295448A (en)	2020-02-21	2022-10-01	Harpoon Therapeutics Inc	flt3 binding proteins and methods of use
MX2022010461A (es)	2020-02-24	2022-12-13	Immatics Us Inc	Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas.
JP2023514654A (ja)	2020-02-25	2023-04-06	ブイアイビーブイゼットダブリュ	ロイシンリッチリピートキナーゼ２のアロステリック調節因子
WO2021173674A1 (en)	2020-02-26	2021-09-02	A2 Biotherapeutics, Inc.	Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
BR112022016633A2 (pt)	2020-02-27	2022-12-13	Novartis Ag	Métodos para produzir células que expressam receptor de antígeno quimérico
US20230256017A1 (en)	2020-02-27	2023-08-17	Jennifer Brogdon	Methods of making chimeric antigen receptor-expressing cells
CA3173527A1 (en)	2020-03-10	2021-09-16	Massachusetts Institute Of Technology	Methods for generating engineered memory-like nk cells and compositions thereof
JP2023517889A (ja)	2020-03-10	2023-04-27	マサチューセッツインスティテュートオブテクノロジー	ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
DE102020111571A1 (de)	2020-03-11	2021-09-16	Immatics US, Inc.	Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CA3175140A1 (en)	2020-03-12	2021-09-16	Immune-Onc Therapeutics, Inc.	Novel anti-lilrb4 antibodies and derivative products
CN115003333A (zh)	2020-03-13	2022-09-02	江苏恒瑞医药股份有限公司	Pvrig结合蛋白及其医药用途
US11365239B2 (en)	2020-03-20	2022-06-21	Tsb Therapeutics (Beijing) Co., Ltd.	Anti-SARS-COV-2 antibodies and uses thereof
IL296330A (en)	2020-03-20	2022-11-01	Glaxosmithkline Ip Dev Ltd	Method for detecting polysorbates
CN116249549A (zh)	2020-03-27	2023-06-09	诺华股份有限公司	用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
EP4126971A1 (en)	2020-03-30	2023-02-08	Ablynx N.V.	Method for the production and purification of multivalent immunoglobulin single variable domains
CN113461817B (zh)	2020-03-31	2025-04-18	苏州泽璟生物制药股份有限公司	一种抗人cd47抗体及其抗原结合片段、制备方法和应用
AU2021250446A1 (en)	2020-03-31	2022-11-17	Biotalys NV	Anti-fungal polypeptides
CN116710146A (zh)	2020-04-03	2023-09-05	威特拉公司	抗体分子-药物偶联物及其用途
EP4132971A1 (en)	2020-04-09	2023-02-15	Merck Sharp & Dohme LLC	Affinity matured anti-lap antibodies and uses thereof
MX2022012752A (es)	2020-04-15	2023-01-16	Voyager Therapeutics Inc	Compuestos de union a tau.
US20230416344A1 (en)	2020-04-16	2023-12-28	Alexion Pharmaceuticals, Inc.	Methods for treating a complement mediated disorder caused by viruses
US20230279115A1 (en)	2020-04-22	2023-09-07	Mabwell (shanghai) Bioscience Co., Ltd.	Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
KR20230028242A (ko)	2020-04-24	2023-02-28	마렝고 테라퓨틱스, 인크.	T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
CN116457368A (zh)	2020-05-01	2023-07-18	匹兹堡大学联邦高等教育系统	用于鉴定纳米抗体和纳米抗体亲和力的组合物和方法
CA3181963A1 (en)	2020-05-04	2021-11-11	Immunorizon Ltd.	Precursor tri-specific antibody constructs and methods of use thereof
CA3180683A1 (en)	2020-05-12	2021-11-18	Inserm (Institut National De La Sante Et De La Recherche Medicale)	New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
WO2021229104A1 (en)	2020-05-15	2021-11-18	Université de Liège	Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2021236658A1 (en)	2020-05-19	2021-11-25	Boehringer Ingelheim International Gmbh	Binding molecules for the treatment of cancer
EP4153192B8 (en)	2020-05-19	2024-09-04	Institut Curie	Antagonist of cd44/hyaluronic acid pathway for use in a method for the treatment of cytokine release syndrome
EP3916088A1 (en)	2020-05-28	2021-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Fusion proteins comprising the sars-cov-2 3clpro catalytic domain and their uses for screening anti-sars-cov-2 agents
CA3180060A1 (en)	2020-05-29	2021-12-02	Zongmin ZHAO	Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
CN111647077B (zh)	2020-06-02	2021-02-09	深圳市因诺赛生物科技有限公司	新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用
CR20220611A (es)	2020-06-02	2023-06-07	Arcus Biosciences Inc	Anticuerpos anti-tigit
US20230332104A1 (en)	2020-06-11	2023-10-19	Novartis Ag	Zbtb32 inhibitors and uses thereof
CN116157510A (zh)	2020-06-17	2023-05-23	詹森生物科技公司	用于制造多能干细胞的材料和方法
WO2021255204A1 (en)	2020-06-18	2021-12-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	New strategy for treating pancreatic cancer
JP2023531722A (ja)	2020-06-24	2023-07-25	ビステラ，インコーポレイテッド	Ａｐｒｉｌに対する抗体分子およびその使用
US20230265211A1 (en)	2020-06-29	2023-08-24	Inserm (Institut National De La Santé Et De Ls Recherche Médicale)	Anti-protein s single-domain antibodies and polypeptides comprising thereof
WO2022003156A1 (en)	2020-07-02	2022-01-06	Oncurious Nv	Ccr8 non-blocking binders
WO2022006219A2 (en)	2020-07-02	2022-01-06	Trustees Of Tufts College	Vhh polypeptides that bind to clostridium difficile toxin b and methods of use thereof
AU2021302199A1 (en)	2020-07-03	2023-02-23	Suzhou Alphamab Co., Ltd.	Coagulation factor XI (FXI) binding protein
PH12023550015A1 (en)	2020-07-16	2024-03-11	Novartis Ag	Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
US20240209089A1 (en)	2020-07-21	2024-06-27	Suzhou Smartnuclide Biopharmaceutical Co., Ltd.	Cd8 binding polypeptide and use thereof
JP2023535024A (ja)	2020-07-23	2023-08-15	オタープロシーナリミテッド	抗ａベータ抗体
WO2022026592A2 (en)	2020-07-28	2022-02-03	Celltas Bio, Inc.	Antibody molecules to coronavirus and uses thereof
EP4189061A1 (en)	2020-07-31	2023-06-07	Biotalys NV	Methods of increasing recombinant protein yields
WO2022035722A1 (en)	2020-08-10	2022-02-17	Janssen Biotech, Inc.	Materials and methods for producing bioengineered virus specific lymphocytes
EP4196139A2 (en)	2020-08-12	2023-06-21	Actym Therapeutics, Inc.	Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
US20220056411A1 (en)	2020-08-21	2022-02-24	Immatics US, Inc.	Methods for isolating cd8+ selected t cells
AU2021331075A1 (en)	2020-08-26	2023-04-06	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
CA3190766A1 (en)	2020-08-26	2022-03-03	Marengo Therapeutics, Inc.	Antibody molecules that bind to nkp30 and uses thereof
GB2616354A (en)	2020-08-26	2023-09-06	Marengo Therapeutics Inc	Methods of detecting TRBC1 or TRBC2
EP4204020A1 (en)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Method of treating psma-expressing cancers
US20230321285A1 (en)	2020-08-31	2023-10-12	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
CA3195367A1 (en)	2020-09-14	2022-03-17	Vor Biopharma Inc.	Single domain antibodies against cd33
WO2022060806A1 (en)	2020-09-16	2022-03-24	Obsidian Therapeutics, Inc.	Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
US20240325562A1 (en)	2020-09-16	2024-10-03	Linxis B.V.	Internalizing binding molecules
WO2022063947A1 (en)	2020-09-24	2022-03-31	Vib Vzw	Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en)	2020-09-24	2022-03-31	Vib Vzw	Biomarker for anti-tumor therapy
CA3195687A1 (en)	2020-09-25	2022-03-31	Ablynx Nv	Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
JP2023545520A (ja)	2020-10-14	2023-10-30	ビリジアンセラピューティクス，インコーポレイテッド	甲状腺眼疾患を治療するための組成物及び方法
WO2022084399A1 (en)	2020-10-21	2022-04-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	C-terminal sparc fragments for treating cancer
AR123862A1 (es)	2020-10-21	2023-01-18	Boehringer Ingelheim Int	Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares
US20230398149A1 (en)	2020-11-04	2023-12-14	Celgene Corporation	Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
AU2021373366A1 (en)	2020-11-06	2023-06-01	Novartis Ag	Cd19 binding molecules and uses thereof
CN116390933A (zh)	2020-11-06	2023-07-04	诺华股份有限公司	治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法
CN112480248B (zh)	2020-11-24	2023-05-05	三优生物医药(上海)有限公司	与cld18a2特异性结合的分子
WO2022117569A1 (en)	2020-12-02	2022-06-09	Oncurious Nv	A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2024508207A (ja)	2020-12-02	2024-02-26	ブイアイビーブイゼットダブリュ	がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022120160A1 (en)	2020-12-04	2022-06-09	Celgene Corporation	Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
PH12023500013A1 (en)	2020-12-04	2024-03-11	Tidal Therapeutics Inc	Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
EP4255466A1 (en)	2020-12-04	2023-10-11	Visterra, Inc.	Methods of using interleukin-2 agents
WO2022130182A1 (en)	2020-12-14	2022-06-23	Novartis Ag	Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
IL303745A (en)	2020-12-17	2023-08-01	Ose Immunotherapeutics	Bifunctional anti-pd1/il-7 molecules
WO2022129637A1 (en)	2020-12-18	2022-06-23	Ablynx Nv	T cell recruiting polypeptides based on tcr alpha/beta reactivity
IL303783A (en)	2020-12-18	2023-08-01	Sanofi Sa	Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
KR20230123497A (ko)	2020-12-18	2023-08-23	아블린쓰 엔.브이.	IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드
GB202020502D0 (en)	2020-12-23	2021-02-03	Vib Vzw	Antibody composistion for treatment of corona virus infection
WO2022136650A1 (en)	2020-12-24	2022-06-30	Oncurious Nv	Murine cross-reactive human ccr8 binders
EP4267618A1 (en)	2020-12-24	2023-11-01	Vib Vzw	Non-blocking human ccr8 binders
EP4267617A1 (en)	2020-12-24	2023-11-01	Vib Vzw	Human ccr8 binders
AU2022211021A1 (en)	2021-01-20	2023-08-03	Visterra, Inc.	Interleukin-2 mutants and uses thereof
GB2603166A (en)	2021-01-29	2022-08-03	Thelper As	Therapeutic and Diagnostic Agents and Uses Thereof
JP2024505049A (ja)	2021-01-29	2024-02-02	ノバルティスアーゲー	抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
IL304904A (en)	2021-02-01	2023-10-01	St Phi Therapeutics Co Ltd	Target protein degradation system and its use
CN117794566A (zh)	2021-02-05	2024-03-29	Vib研究所	沙贝病毒结合剂
WO2022170063A1 (en)	2021-02-05	2022-08-11	Salubris Biotherapeutics, Inc.	Il-15 fusion proteins and methods of making and using same
KR20230141853A (ko)	2021-02-05	2023-10-10	브이아이비 브이지더블유	사베코바이러스 결합제
WO2022171777A1 (en)	2021-02-12	2022-08-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for prognosis and treating a patient suffering from cancer
CA3211257A1 (en)	2021-02-17	2022-08-25	Vib Vzw	Inhibition of slc4a4 in the treatment of cancer
BR112023016706A2 (pt)	2021-02-19	2023-10-31	Seoul Nat Univ R&Db Foundation	Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
JP7773239B2 (ja)	2021-02-19	2025-11-19	シャペロンインク．	Ｐｄ－ｌ１及びｃｄ４７に対する二重特異性単一ドメイン抗体及びその用途
CA3209052A1 (en)	2021-02-19	2022-08-25	Rafael Cristian CASELLAS	Single domain antibodies that neutralize sars-cov-2
AU2022222994B2 (en)	2021-02-19	2025-11-27	Shaperon Inc.	Single domain antibody against cd47 and use thereof
EP4294516A1 (en)	2021-02-19	2023-12-27	Vib Vzw	Cation-independent mannose-6-phosphate receptor binders
WO2022195551A1 (en)	2021-03-18	2022-09-22	Novartis Ag	Biomarkers for cancer and methods of use thereof
WO2022199804A1 (en)	2021-03-24	2022-09-29	Vib Vzw	Nek6 inhibition to treat als and ftd
GB202104104D0 (en)	2021-03-24	2021-05-05	Liliumx Ltd	Platform and method
US20240376224A1 (en)	2021-04-02	2024-11-14	The Regents Of The University Of California	Antibodies against cleaved cdcp1 and uses thereof
WO2022216524A1 (en)	2021-04-07	2022-10-13	Century Therapeutics, Inc.	Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
CN117441010A (zh)	2021-04-07	2024-01-23	世纪治疗股份有限公司	从诱导多能干细胞产生α-βT细胞的组合物和方法
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
JP2024519515A (ja)	2021-04-07	2024-05-15	センチュリーセラピューティクス，インコーポレイテッド	人工多能性幹細胞からガンマ－デルタｔ細胞を生成するための組成物および方法
KR20240004462A (ko)	2021-04-08	2024-01-11	마렝고 테라퓨틱스, 인크.	Tcr에 결합하는 다기능성 분자 및 이의 용도
US20240182571A1 (en)	2021-04-09	2024-06-06	Ose Immunotherapeutics	New scaffold for bifunctional molecules with improved properties
EP4320229A1 (en)	2021-04-09	2024-02-14	Stichting Radboud Universiteit	Off the shelf proximity biotinylation enzyme
WO2022214652A1 (en)	2021-04-09	2022-10-13	Ose Immunotherapeutics	Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
US20240190993A1 (en)	2021-04-14	2024-06-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	New method to improve the anti-tumoral activity of macrophages
EP4322938A1 (en)	2021-04-14	2024-02-21	Institut National de la Santé et de la Recherche Médicale (INSERM)	New method to improve nk cells cytotoxicity
AU2022257093A1 (en)	2021-04-16	2023-11-02	Celgene Corporation	T cell therapy in patients who have had prior stem cell transplant
TW202307007A (zh)	2021-05-04	2023-02-16	美商再生元醫藥公司	多特異性fgf21受體促效劑及其等用途
WO2022236134A1 (en)	2021-05-07	2022-11-10	Surface Oncology, Inc.	Anti-il-27 antibodies and uses thereof
WO2022242892A1 (en)	2021-05-17	2022-11-24	Université de Liège	Anti-cd38 single-domain antibodies in disease monitoring and treatment
EP4340879A4 (en)	2021-05-20	2025-03-26	Dianthus Therapeutics OpCo, Inc.	Antibodies that bind to c1s and uses thereof
WO2022253910A1 (en)	2021-06-02	2022-12-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	A new method to treat an inflammatory skin disease
JP2024523436A (ja)	2021-06-16	2024-06-28	上海▲シン▼湾生物科技有限公司	Ａｘｌタンパク質を標的とする抗体及びその抗原結合断片、その調製方法と使用
US12275798B2 (en)	2021-06-17	2025-04-15	Boehringer Ingelheim International Gmbh	Tri-specific binding molecules
CA3224912A1 (en)	2021-06-22	2022-12-29	Merck Patent Gmbh	Vhh-based nkp30 binders
WO2022269473A1 (en)	2021-06-23	2022-12-29	Janssen Biotech, Inc.	Materials and methods for hinge regions in functional exogenous receptors
CN114230665B (zh)	2021-06-23	2024-03-22	苏州智核生物医药科技有限公司	CD8α结合多肽及其用途
WO2022268993A1 (en)	2021-06-23	2022-12-29	Vib Vzw	Means and methods for selection of specific binders
US20240343811A1 (en)	2021-06-29	2024-10-17	Shandong Simcere Biopharmacutical Co., Ltd.	Cd16 antibody and use thereof
WO2023288046A1 (en)	2021-07-15	2023-01-19	President And Fellows Of Harvard College	Compositions and methods relating to cells with adhered particles
CA3227972A1 (en)	2021-07-30	2023-02-02	Shandong Simcere Biopharmaceutical Co., Ltd.	Anti-pvrig/anti-tigit bispecific antibodies and applications thereof
EP4377352A2 (en)	2021-07-30	2024-06-05	Vib Vzw	Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
CN118019548A (zh)	2021-08-06	2024-05-10	蒙彼利埃癌症研究所	用于治疗癌症的方法
WO2023019171A1 (en)	2021-08-10	2023-02-16	Viridian Therapeutics, Inc.	Compositions, doses, and methods for treatment of thyroid eye disease
WO2023023220A1 (en)	2021-08-20	2023-02-23	Alexion Pharmaceuticals, Inc.	Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
WO2023023227A1 (en)	2021-08-20	2023-02-23	Alexion Pharmaceuticals, Inc.	Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
JP2024531462A (ja)	2021-08-24	2024-08-29	江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司	Ｆａｐ／ｃｄ４０結合分子及びその医薬的使用
WO2023041985A2 (en)	2021-09-15	2023-03-23	New York University In Abu Dhabicorporation	Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
TW202328195A (zh)	2021-09-15	2023-07-16	大陸商江蘇恆瑞醫藥股份有限公司	特異性結合ｐｄ－１的蛋白及其醫藥用途
US20240376207A1 (en)	2021-09-15	2024-11-14	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
US20240316061A1 (en)	2021-09-17	2024-09-26	Institut Curie	Bet inhibitors for treating pab1 deficient cancer
EP4405396A2 (en)	2021-09-20	2024-07-31	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
US20250134952A1 (en)	2021-09-20	2025-05-01	Institut National de la Santé et de la Recherche Médicale	Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023057484A1 (en)	2021-10-06	2023-04-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
WO2023057601A1 (en)	2021-10-06	2023-04-13	Biotalys NV	Anti-fungal polypeptides
CA3233824A1 (en)	2021-10-08	2023-04-13	Samir Mitragotri	Ionic liquids for drug delivery
CA3234995A1 (en)	2021-10-14	2023-04-20	Latticon (Suzhou) Biopharmaceuticals Co., Ltd.	Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
WO2023073099A1 (en)	2021-10-28	2023-05-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method to improve phagocytosis
WO2023078906A1 (en)	2021-11-03	2023-05-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating acute myeloid leukemia
EP4177266A1 (en)	2021-11-05	2023-05-10	Katholieke Universiteit Leuven	Neutralizing anti-sars-cov-2 human antibodies
WO2023079137A1 (en)	2021-11-05	2023-05-11	Katholieke Universiteit Leuven	Neutralizing anti-sars-cov-2 human antibodies
JP2024542409A (ja)	2021-11-09	2024-11-15	オーエスイー・イミュノセラピューティクス	Ｃｌｅｃ－１リガンドの同定及びその使用
JP2024542173A (ja)	2021-11-09	2024-11-13	アクティム・セラピューティクス・インコーポレイテッド	マクロファージを処置に適している表現型に変換するための免疫刺激細菌および処置のための対象の同定のためのコンパニオン診断法
EP4180518A1 (en)	2021-11-12	2023-05-17	Istituto Europeo di Oncologia S.r.l.	T cells and uses thereof
US20250034559A1 (en)	2021-11-17	2025-01-30	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
EP4433089A1 (en)	2021-11-19	2024-09-25	Institut Curie	Methods for the treatment of hrd cancer and brca-associated cancer
EP4437547A1 (en)	2021-11-22	2024-10-02	Ablynx N.V.	Obtaining sequence information for target multivalent immunoglobulin single variable domains
WO2023089159A1 (en)	2021-11-22	2023-05-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	New strategy targeting stroma/tumor cell crosstalk to treat a cancer
WO2023097254A1 (en)	2021-11-24	2023-06-01	Visterra, Inc.	Engineered antibody molecules to cd138 and uses thereof
JP2024544598A (ja)	2021-11-24	2024-12-03	ノバルティスアーゲー	アデノ随伴ウイルス形質導入の調節因子及びその使用
US20250026842A1 (en)	2021-11-29	2025-01-23	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Modified protein or polypeptide
EP4442273A1 (en)	2021-11-30	2024-10-09	Suzhou Alphamab Co., Ltd.	Method for preventing and/or treating thromboembolic diseases
CA3238574A1 (en)	2021-12-01	2023-06-08	Gregory Babcock	Methods of using interleukin-2 agents
WO2023099763A1 (en)	2021-12-03	2023-06-08	Institut Curie	Sirt6 inhibitors for use in treating resistant hrd cancer
CN118696058A (zh)	2021-12-03	2024-09-24	山东先声生物制药有限公司	抗bcma纳米抗体及其应用
IL313473A (en)	2021-12-15	2024-08-01	Interius Biotherapeutics Inc	Pseudotyped viral particles, compositions comprising the same, and uses thereof
EP4448574A1 (en)	2021-12-17	2024-10-23	Ablynx N.V.	Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123
JP2025501206A (ja)	2021-12-31	2025-01-17	山▲東▼先声生物制▲薬▼有限公司	Ｇｐｒｃ５ｄ抗体及びその応用
EP4209508A1 (en)	2022-01-11	2023-07-12	Centre national de la recherche scientifique	Nanobodies for the deneddylating enzyme nedp1
EP4463479A1 (en)	2022-01-12	2024-11-20	Vib Vzw	Human ntcp binders for therapeutic use and liver-specific targeted delivery
WO2023147470A2 (en)	2022-01-28	2023-08-03	Georgiamune Inc.	Antibodies to programmed cell death protein 1 that are pd-1 agonists
GB202201137D0 (en)	2022-01-28	2022-03-16	Thelper As	Therapeutic and diagnostic agents and uses thereof
WO2023148291A1 (en)	2022-02-02	2023-08-10	Biotalys NV	Methods for genome editing
TW202342548A (zh)	2022-02-07	2023-11-01	美商威特拉公司	抗獨特型(anti-idiotype)抗體分子及其用途
WO2023148397A1 (en)	2022-02-07	2023-08-10	Vib Vzw	Engineered stabilizing aglycosylated fc-regions
WO2023151894A1 (en)	2022-02-11	2023-08-17	Henkel Ag & Co. Kgaa	Process for the synthesis of alpha-methylene-gamma-butyrolactone
WO2023164487A1 (en)	2022-02-22	2023-08-31	Brown University	Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
EP4496815A1 (en)	2022-03-23	2025-01-29	Bodhi Bio LLC	Compositions and methods for antigen-specific therapy
JP2025510997A (ja)	2022-03-30	2025-04-15	ノバルティスアーゲー	抗ナトリウム利尿ペプチド受容体１（ｎｐｒ１）抗体を使用して障害を治療する方法
WO2023201238A1 (en)	2022-04-11	2023-10-19	Vor Biopharma Inc.	Binding agents and methods of use thereof
WO2023198806A1 (en)	2022-04-13	2023-10-19	Ose Immunotherapeutics	New class of molecules for selective clearance of antibody
EP4508082A1 (en)	2022-04-13	2025-02-19	Vib Vzw	An ltbr agonist in combination therapy against cancer
EP4507779A1 (en)	2022-04-14	2025-02-19	Institut National de la Santé et de la Recherche Médicale	Methods for controlling the tumor cell killing by light
AU2023262513A1 (en)	2022-04-25	2024-12-05	Visterra, Inc.	Antibody molecules to april and uses thereof
EP4514390A1 (en)	2022-04-28	2025-03-05	The United States of America, as represented by the Secretary, Department of Health and Human Services	Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2
JP2025516262A (ja)	2022-05-02	2025-05-27	アーカスバイオサイエンシズインコーポレイティド	抗ｔｉｇｉｔ抗体及びその使用
WO2023213751A1 (en)	2022-05-02	2023-11-09	Umc Utrecht Holding B.V	Single domain antibodies for the detection of plasmin-cleaved vwf
WO2023216981A1 (zh)	2022-05-07	2023-11-16	北京拓界生物医药科技有限公司	松弛素或类似物的融合蛋白及其医药用途
US20250223326A1 (en)	2022-05-10	2025-07-10	Institut National de la Santé et de la Recherche Médicale	Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
WO2023220641A2 (en)	2022-05-11	2023-11-16	Juno Therapeutics, Inc.	Methods and uses related to t cell therapy and production of same
CN119546628A (zh)	2022-05-11	2025-02-28	再生元制药公司	多特异性结合分子前蛋白及其用途
EP4522757A2 (en)	2022-05-13	2025-03-19	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
CN119213034A (zh)	2022-05-17	2024-12-27	苏州创胜医药集团有限公司	双功能蛋白质及其制剂和用途
US20250313611A1 (en)	2022-05-18	2025-10-09	Vib Vzw	Sarbecovirus spike s2 subunit binders
EP4527853A1 (en)	2022-05-19	2025-03-26	Shaperon Inc.	Bispecific humanized single domain antibody to pd-l1 and cd47, and use thereof
WO2023224715A1 (en)	2022-05-19	2023-11-23	Massachusetts Institute Of Technology	Car cells targeting an inserted ligand
WO2023230128A1 (en)	2022-05-25	2023-11-30	Surface Oncology, Inc.	Use of anti-il-27 antibodies
US20240025987A1 (en)	2022-05-25	2024-01-25	Surface Oncology, Inc.	Use of anti-il-27 antibodies
US20250345432A1 (en)	2022-05-25	2025-11-13	Celgene Corporation	Method for predicting response to a t cell therapy
CA3250546A1 (en)	2022-05-30	2023-12-07	Ose Immunotherapeutics	IL7R MODULATOR ACTIVITY BIOMARKERS
KR20250019077A (ko)	2022-05-31	2025-02-07	퓨쳐진 바이오파머쓰티컬 (베이징) 코., 엘티디.	항-cd40 항체 및 항-pd-l1×cd40 이중특이성 항체 및 이의 용도
JP2025522351A (ja)	2022-06-06	2025-07-15	山▲東▼先声生物制▲薬▼有限公司	Ｂｃｍａ、ｇｐｒｃ５ｄ及びｔ細胞を標的とする多重特異性抗体並びにその応用
CA3258639A1 (en)	2022-06-07	2023-12-14	Regeneron Pharma	Multispecific molecules to modulate T lymphocyte activity, and their uses
WO2023240124A1 (en)	2022-06-07	2023-12-14	Regeneron Pharmaceuticals, Inc.	Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240156A1 (en)	2022-06-08	2023-12-14	Tidal Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
US20240109965A1 (en)	2022-06-14	2024-04-04	Ablynx N.V.	Immunoglobulin single variable domains targeting t cell receptor
WO2024003873A1 (en)	2022-06-30	2024-01-04	Intrexon Actobiotics Nv D/B/A Precigen Actobio	Single variable domain antibodies against tumor necrosis factor-alpha
EP4299124A1 (en)	2022-06-30	2024-01-03	Universite De Montpellier	Anti-mglur2 nanobodies for use as biomolecule transporter
EP4299125A1 (en)	2022-06-30	2024-01-03	Universite De Montpellier	Anti-mglur2 biparatopic nanobodies and uses thereof
JP2025523630A (ja)	2022-07-04	2025-07-23	ブイアイビーブイゼットダブリュ	血液－脳脊髄液関門通過抗体
PE20251082A1 (es)	2022-07-08	2025-04-10	Novo Nordisk As	Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
AR129879A1 (es)	2022-07-08	2024-10-09	Novo Nordisk As	Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
PE20250669A1 (es)	2022-07-15	2025-03-04	Boehringer Ingelheim Int	Moleculas de union para el tratamiento del cancer
KR20250040019A (ko)	2022-07-18	2025-03-21	아블린쓰	Cx3cr1 결합 화합물, 이의 용도, 및 관련 방법
CA3262611A1 (en)	2022-07-22	2024-01-25	Janssen Biotech Inc	IMPROVED TRANSFER OF GENETIC INSTRUCTIONS TO EFFECTOR IMMUNE CELLS
WO2024026284A2 (en)	2022-07-25	2024-02-01	Interius Biotherapeutics, Inc.	Mutated polypeptides, compositions comprising the same, and uses thereof
JP2025526384A (ja)	2022-07-27	2025-08-13	アブリンクスエン．ヴェー．	新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド
CN119855827A (zh)	2022-08-01	2025-04-18	Ose免疫疗法公司	异源二聚Fc-CLEC-1融合分子及其用途
JP2025525886A (ja)	2022-08-02	2025-08-07	オーエスイー・イミュノセラピューティクス	Ｃｄ２８に対する多機能性分子
TW202435912A (zh)	2022-08-03	2024-09-16	美商航海家醫療公司	用於穿過血腦屏障之組合物及方法
WO2024028476A1 (en)	2022-08-05	2024-02-08	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of th2-mediated diseases
WO2024037910A1 (en)	2022-08-17	2024-02-22	Institut National de la Santé et de la Recherche Médicale	Syk inhibitors for use in the treatment of cancer
EP4577578A1 (en)	2022-08-22	2025-07-02	Abdera Therapeutics Inc.	Dll3 binding molecules and uses thereof
EP4580658A1 (en)	2022-08-31	2025-07-09	Institut National de la Santé et de la Recherche Médicale	Method to generate more efficient car-t cells
WO2024049951A1 (en)	2022-08-31	2024-03-07	Alexion Pharmaceuticals, Inc.	Dosage and administration of fusion polypeptides for treatment of sickle cell disease
JP2025529210A (ja)	2022-09-01	2025-09-04	ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド	アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
CA3266977A1 (en)	2022-09-06	2024-03-14	Alexion Pharma Inc	DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)
CA3266599A1 (en)	2022-09-07	2024-11-07	Quantitative Biosciences Inc	UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
WO2024055034A1 (en)	2022-09-09	2024-03-14	Yale University	Proteolysis targeting antibodies and methods of use thereof
KR20250069606A (ko)	2022-09-15	2025-05-19	보이저 테라퓨틱스, 인크.	타우 결합 화합물
CA3266372A1 (en)	2022-09-15	2024-03-21	Novartis Ag	TREATMENT OF AUTOIMMUNE DISORDERS USING CHIMERIC ANTIGEN RECEPTOR THERAPY
WO2024068744A1 (en)	2022-09-27	2024-04-04	Vib Vzw	Antivirals against human parainfluenza virus
EP4594344A2 (en)	2022-09-28	2025-08-06	Valink Therapeutics Ltd	Multivalent proteins and screening methods
TW202430561A (zh)	2022-09-30	2024-08-01	法商賽諾菲公司	抗cd28抗體
WO2024074713A1 (en)	2022-10-07	2024-04-11	Institut National de la Santé et de la Recherche Médicale	Method to generate improving car-t cells
WO2024083843A1 (en)	2022-10-18	2024-04-25	Confo Therapeutics N.V.	Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024088424A1 (zh)	2022-10-28	2024-05-02	嘉和生物药业有限公司	新型抗ctla4抗体
EP4612180A1 (en)	2022-10-31	2025-09-10	Stichting Amsterdam UMC	Single domain anti-cd169 antibodies
EP4613768A1 (en)	2022-11-02	2025-09-10	Suzhou Alphamab Co., Ltd	Gipr binding protein and use thereof
WO2024101989A1 (en)	2022-11-08	2024-05-16	Stichting Amsterdam UMC	Activation inducible antigen receptors for adoptive immunotherapy
WO2024102962A1 (en)	2022-11-10	2024-05-16	Immuvia Inc	Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
JP2025537809A (ja)	2022-11-15	2025-11-20	アイメック・ヴェーゼットウェー	液滴操作のための方法およびシステム
KR20250152696A (ko)	2022-11-21	2025-10-23	다이안서스 테라퓨틱스 오피씨오, 인코포레이티드.	C1s에 결합하는 항체 및 이의 용도
AU2023404602A1 (en)	2022-11-29	2025-05-29	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Cldn18.2/4-1bb binding protein and medical use thereof
IL319951A (en)	2022-11-30	2025-05-01	Integral Molecular Inc	Antibodies targeting claudin 6, including its bispecific formats
EP4626401A1 (en)	2022-12-01	2025-10-08	Generation Bio Co.	Stealth lipid nanoparticle compositions for cell targeting
WO2024123963A2 (en)	2022-12-07	2024-06-13	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing monoclonal antibodies against western, eastern, and venezuelan equine encephalitis virus (eev)
WO2024126363A1 (en)	2022-12-12	2024-06-20	Institut National de la Santé et de la Recherche Médicale	Image-based high-content screening methods for identifying compounds targeting apicomplexan parasites
EP4634214A1 (en)	2022-12-15	2025-10-22	Aarhus Universitet	Synthetic activation of multimeric transmembrane receptors
US12195546B2 (en)	2022-12-19	2025-01-14	Sanofi	CD28/OX40 bispecific antibodies
CN120380012A (zh)	2022-12-19	2025-07-25	Umc乌德勒支控股有限公司	Btn2a1结合肽
EP4638502A2 (en)	2022-12-21	2025-10-29	Genzyme Corporation	Anti-pd-1×4-1bb binding proteins
WO2024133723A1 (en)	2022-12-22	2024-06-27	Institut National de la Santé et de la Recherche Médicale	Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
WO2024133937A1 (en)	2022-12-22	2024-06-27	Biotalys NV	Methods for genome editing
TW202440614A (zh)	2022-12-23	2024-10-16	比利時商艾伯霖克斯公司	基於蛋白質的接合載體
EP4640715A1 (en)	2022-12-23	2025-10-29	Chimagen Biosciences, Ltd	Multi-specific polypeptide complex targeting gprc5d
TW202440159A (zh)	2022-12-29	2024-10-16	大陸商蘇州創勝醫藥集團有限公司	含有治療性抗體的藥物製劑及其用途
WO2024145551A1 (en)	2022-12-29	2024-07-04	Biotalys NV	Agrochemical compositions
EP4642233A1 (en)	2022-12-30	2025-11-05	Biotalys NV	Agglomerate
WO2024143925A1 (ko)	2022-12-30	2024-07-04	연세대학교 산학협력단	Rnase a에 특이적으로 결합하는 항체 또는 펩티드, 및 rnase a 검출 면역분석 장치 및 방법 그리고 rnase a 포집 방법
WO2024141638A1 (en)	2022-12-30	2024-07-04	Biotalys NV	Self-emulsifiable concentrate
WO2024141641A2 (en)	2022-12-30	2024-07-04	Biotalys NV	Secretion signals
AU2024207151A1 (en)	2023-01-09	2025-06-19	Odyssey Therapeutics, Inc.	Anti-tnfr2 antigen-binding proteins and uses thereof
KR20250133913A (ko)	2023-01-09	2025-09-09	베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드	TGFβ1 결합 분자, GARP-TGFβ1 결합 분자 및 이의 의학적 용도
EP4649092A1 (en)	2023-01-13	2025-11-19	Regeneron Pharmaceuticals, Inc.	Fgfr3 binding molecules and methods of use thereof
TW202434629A (zh)	2023-01-26	2024-09-01	愛爾蘭商歐薩爾普羅席納有限公司	以抗類澱粉β (ABETA)抗體治療神經病症之方法
WO2024156888A1 (en)	2023-01-27	2024-08-02	Vib Vzw	Cd163-binding conjugates
EP4655323A1 (en)	2023-01-27	2025-12-03	Vrije Universiteit Brussel	Cd8b-binding polypeptides
KR20250143339A (ko)	2023-02-06	2025-10-01	메르크 파텐트 게엠베하	VHH-기반 NKp46 결합제
WO2024168061A2 (en)	2023-02-07	2024-08-15	Ayan Therapeutics Inc.	Antibody molecules binding to sars-cov-2
EP4662246A1 (en)	2023-02-09	2025-12-17	Seni-Preps B.V.	Immunoglobulin single variable domains that inhibit urease and use thereof
CN121013866A (zh)	2023-02-10	2025-11-25	阿穆尼克斯制药公司	靶向前列腺特异性膜抗原（psma）的组合物及其制备和使用方法
TW202448926A (zh)	2023-02-17	2024-12-16	比利時商艾伯霖克斯公司	結合新生兒fc受體之多肽
WO2024175787A1 (en)	2023-02-24	2024-08-29	Vrije Universiteit Brussel	Anti-inflammatory pannexin 1 channel inhibitors
WO2024184810A1 (en)	2023-03-06	2024-09-12	Beigene Switzerland Gmbh	Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
AR132064A1 (es)	2023-03-06	2025-05-21	Beigene Switzerland Gmbh	Anticuerpos anti-cldn6 y métodos de uso
TW202436345A (zh)	2023-03-06	2024-09-16	瑞士商百濟神州瑞士有限責任公司	抗ｃｄ３多特異性抗體及使用方法
CN120858176A (zh)	2023-03-07	2025-10-28	居里研究所	Brca相关癌症中的ung/udg抑制
WO2024184479A1 (en)	2023-03-08	2024-09-12	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of food allergy
TW202444757A (zh)	2023-03-14	2024-11-16	美商奧迪希治療公司	抗cd25抗原結合蛋白及其用途
US20240344078A1 (en)	2023-03-14	2024-10-17	Aarhus Universitet	Genetically altered nfr5 receptor kinases
WO2024194673A1 (en)	2023-03-21	2024-09-26	Institut Curie	Methods for the treatment of dedifferentiated liposarcoma
WO2024194401A1 (en)	2023-03-21	2024-09-26	Institut Curie	Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194402A1 (en)	2023-03-21	2024-09-26	Institut Curie	Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
AU2024240821A1 (en)	2023-03-23	2025-11-06	Bodhi Bio Llc	Compositions and methods for antigen-specific therapy
CN120958023A (zh)	2023-03-24	2025-11-14	赛诺菲	通过阻断il-13和tslp治疗哮喘
EP4435005A1 (en)	2023-03-24	2024-09-25	Sanofi	Asthma treatment by blocking il-13 and tslp
AU2024245676A1 (en)	2023-03-30	2025-10-09	272BIO Limited	Gnrh-binding polypeptides and uses thereof
AU2024243709A1 (en)	2023-04-03	2025-11-06	Katholieke Universiteit Leuven	Blood-brain barrier crossing antibodies
WO2024213782A1 (en)	2023-04-13	2024-10-17	Institut Curie	Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024224323A1 (en)	2023-04-24	2024-10-31	King Abdullah University Of Science Of Technology	Compositions, systems and methods for multiplex detection of target biomarkers in a sample
WO2024226829A2 (en)	2023-04-26	2024-10-31	Yale University	Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
CN121079319A (zh)	2023-05-08	2025-12-05	赛诺菲	免疫球蛋白单可变结构域的糖基化
WO2024231348A1 (en)	2023-05-11	2024-11-14	Vib Vzw	Slc4a4/nbce1 inhibitors
WO2024238565A1 (en)	2023-05-15	2024-11-21	Vor Biopharma Inc.	Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
TW202448951A (zh)	2023-05-17	2024-12-16	美商奧迪希治療公司	經修飾之單域抗體
WO2024240162A1 (en)	2023-05-23	2024-11-28	Shanghai Allygen Biologics Co., Ltd.	Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
AU2024274792A1 (en)	2023-05-23	2025-10-23	Sana Biotechnology, Inc.	Tandem fusogens and related lipid particles
WO2024251826A1 (en)	2023-06-05	2024-12-12	Vib Vzw	Glyco-engineered antibody-drug-conjugates comprising an oxime linker
WO2024251783A1 (en)	2023-06-05	2024-12-12	Sanofi	Predicting thermal stabilities of immunoglobulin single variable domains using machine-learning models
WO2024251981A1 (en)	2023-06-09	2024-12-12	Umc Utrecht Holding B.V.	Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
WO2024251983A1 (en)	2023-06-09	2024-12-12	Merck Patent Gmbh	Il-18 mimetics
WO2024256527A1 (en)	2023-06-13	2024-12-19	Institut National de la Santé et de la Recherche Médicale	Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy
WO2024259305A1 (en)	2023-06-14	2024-12-19	The Broad Institute, Inc.	Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
AR133055A1 (es)	2023-06-22	2025-08-20	Ablynx Nv	Dominios variables únicos de inmunoglobulina dirigidos a pd-l1
WO2024261235A1 (en)	2023-06-22	2024-12-26	Ablynx Nv	Chimeric proteins for modulating cytokine receptor activity
WO2024261344A1 (en)	2023-06-23	2024-12-26	Vib Vzw	Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
TW202515917A (zh)	2023-06-29	2025-04-16	美商奧迪希治療公司	抗trailr2抗原結合蛋白及其用途
EP4483951A1 (en)	2023-06-30	2025-01-01	Université de Liège	Single-domain antibody for inhibition of neutrophil elastase activity
AR133188A1 (es)	2023-07-05	2025-09-03	Ablynx Nv	ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025007195A1 (en)	2023-07-05	2025-01-09	CSL Innovation Pty Ltd	Methods of treating or preventing a complication of sickle cell disease
TW202509078A (zh)	2023-07-07	2025-03-01	美商維里迪恩醫療股份有限公司	治療慢性甲狀腺眼病之方法
WO2025024645A1 (en)	2023-07-25	2025-01-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Rapid method for producing antibodies
WO2025034806A1 (en)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032158A1 (en)	2023-08-08	2025-02-13	Institut National de la Santé et de la Recherche Médicale	Method to treat tauopathies
WO2025032112A1 (en)	2023-08-08	2025-02-13	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of type 2-mediated diseases
WO2025032213A1 (en)	2023-08-10	2025-02-13	Ose Immunotherapeutics	Identification of hla-dra as a ligand of clec-1 and uses thereof
WO2025036848A1 (en)	2023-08-11	2025-02-20	Wuxi Biologics (Shanghai) Co., Ltd.	Anti-muc16 antibodies and uses thereof
EP4512243A1 (en)	2023-08-21	2025-02-26	Kymab Limited	Binding molecules
WO2025051767A1 (en)	2023-09-04	2025-03-13	Sanofi	Polypeptides for use in the treatment of glypican-3-expressing tumours
TW202530246A (zh)	2023-09-15	2025-08-01	愛爾蘭商歐賽爾普羅希那有限公司	細胞穿透劑及其用途
GB202314424D0 (en)	2023-09-20	2023-11-01	Cambridge Entpr Ltd	A conjugate
AR133903A1 (es)	2023-09-22	2025-11-12	Ablynx Nv	Agentes de unión de albúmina bi- y multivalentes
WO2025068393A1 (en)	2023-09-27	2025-04-03	Institut Curie	Methods for the treatment of fibrotic related diseases
WO2025073765A1 (en)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from melanoma
WO2025073890A1 (en)	2023-10-06	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Method to capture circulating tumor extracellular vesicles
WO2025078418A1 (en)	2023-10-10	2025-04-17	Nano Tag Biotechnologies Gmbh	Humanized single-domain antibodies binding to epitope tags
WO2025078851A1 (en)	2023-10-11	2025-04-17	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods of treating cognitive deficit
TW202535921A (zh)	2023-10-11	2025-09-16	德商拜恩迪克公司	用於靶向遞送免疫效應子細胞之試劑及方法
TW202515903A (zh)	2023-10-12	2025-04-16	瑞士商百濟神州瑞士有限責任公司	手術前後基於抗ｐｄ－１之治療
NL2036011B1 (en)	2023-10-12	2025-04-30	Synapse Res Institute	Molecules for reversing anti-coagulant activity of direct oral anticoagulants
TW202530265A (zh)	2023-10-13	2025-08-01	美商奧迪希治療公司	抗cdh17抗原結合蛋白及其用途
WO2025093541A1 (en)	2023-10-31	2025-05-08	Ose Immunotherapeutics	Combination of interleukin 7 and tumour associated antigen vaccine
WO2025093683A1 (en)	2023-11-03	2025-05-08	Neuvasq Biotechnologies Sa	Wnt7 signaling agonists
WO2025099632A1 (en)	2023-11-08	2025-05-15	Sanofi	Cd25 based lysosomal degrader and uses thereof
WO2025109176A1 (en)	2023-11-22	2025-05-30	Exevir Bio Bv	Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
WO2025114529A1 (en)	2023-12-01	2025-06-05	Ablynx Nv	Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
WO2025122634A1 (en)	2023-12-05	2025-06-12	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
WO2025125577A1 (en)	2023-12-14	2025-06-19	Vib Vzw	Antibodies against influenza b virus
TW202535948A (zh)	2023-12-17	2025-09-16	美商維里迪恩醫療股份有限公司	用於治療甲狀腺眼病之組合物、劑量及方法
WO2025132833A1 (en)	2023-12-20	2025-06-26	Institut National de la Santé et de la Recherche Médicale	Anti trypsin-3 single domain antibody
US20250236673A1 (en)	2023-12-22	2025-07-24	Ablynx N.V.	Protein-based carriers for site-specific amine conjugation
WO2025133252A1 (en)	2023-12-22	2025-06-26	Ablynx Nv	Immunoglobulin single variable domains targeting ceacam5
WO2025133253A2 (en)	2023-12-22	2025-06-26	Ablynx Nv	Protein-based conjugation carriers for intranuclear delivery
EP4574981A1 (en)	2023-12-22	2025-06-25	Biotalys NV	Anti-fungal vhh antibodies
WO2025151492A1 (en)	2024-01-09	2025-07-17	Viridian Therapeutics, Inc.	Compositions and methods for treatment of thyroid eye disease
WO2025151496A1 (en)	2024-01-09	2025-07-17	Viridian Therapeutics, Inc.	Compositions and methods for treatment of thyroid eye disease
WO2025151502A1 (en)	2024-01-09	2025-07-17	Viridian Therapeutics, Inc.	Modified antibodies
WO2025154058A1 (en)	2024-01-21	2025-07-24	Ibi-Ag Innovative Bio Insecticides Ltd.	Anti-insect hsp70 nanobodies and uses thereof
WO2025154056A1 (en)	2024-01-21	2025-07-24	Ibi-Ag Innovative Bio Insecticides Ltd.	Anti-insect cda nanobodies and uses thereof
WO2025160546A1 (en)	2024-01-26	2025-07-31	The Johns Hopkins University	Dendrimer conjugate compositions for intracellular delivery of antibodies and antibody fragments
WO2025162980A1 (en)	2024-01-30	2025-08-07	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of breast cancer using a jnk-1 inhibitor
WO2025168716A1 (en)	2024-02-07	2025-08-14	Eyebiotech Limited	Compositions, doses, and methods for treatment of ocular diseases
WO2025174825A2 (en)	2024-02-12	2025-08-21	Aera Therapeutics, Inc.	Delivery compositions
WO2025176777A1 (en)	2024-02-20	2025-08-28	Institut Curie	Dut inhibition in homologous recombination deficiency cancer
WO2025178959A1 (en)	2024-02-20	2025-08-28	University Of Georgia Research Foundation, Inc.	Single-domain antibodies and variants thereof against tab1
WO2025181155A1 (en)	2024-02-26	2025-09-04	Vib Vzw	Human beta-glucocerebrosidase binders and uses thereof
EP4658320A1 (en)	2024-02-27	2025-12-10	Bristol-Myers Squibb Company	Anti-ceacam5 antibody drug conjugates
US20250361320A1 (en)	2024-02-27	2025-11-27	Bristol-Myers Squibb Company	Anti-ceacam5 antibodies and uses thereof
WO2025191018A1 (en)	2024-03-13	2025-09-18	Institut National de la Santé et de la Recherche Médicale	Mrgpre binding agent for use in the treatment of inflammatory and pain disorders
WO2025196308A1 (en)	2024-03-22	2025-09-25	Vib Vzw	Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025207946A1 (en)	2024-03-28	2025-10-02	Genzyme Corporation	Polypeptides binding to a specific epitope of the transferrin receptor 1
WO2025212726A2 (en)	2024-04-04	2025-10-09	Compass Therapeutics, Inc.	Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer
WO2025217240A1 (en)	2024-04-10	2025-10-16	Odyssey Therapeutics, Inc.	Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025219231A1 (en)	2024-04-15	2025-10-23	Vib Vzw	Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025224050A1 (en)	2024-04-22	2025-10-30	Institut National de la Santé et de la Recherche Médicale	Methods of treatment of patients suffering from hypomelanosis of ito
WO2025226603A1 (en)	2024-04-22	2025-10-30	Surface Oncology, LLC	Methods for treating cancer using anti-ccr8 antibodies
WO2025224297A1 (en)	2024-04-26	2025-10-30	Institut National de la Santé et de la Recherche Médicale	Antibodies having specificity to tgfbi and uses thereof
WO2025231143A1 (en)	2024-04-30	2025-11-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies against ev-d68
WO2025240335A1 (en)	2024-05-13	2025-11-20	Regeneron Pharmaceuticals, Inc.	Fgfr3 binding molecules and methods of use thereof
WO2025238157A1 (en)	2024-05-15	2025-11-20	Katholieke Universiteit Leuven	Multispecific binding agent suitable for use in cancer immune therapy
WO2025242835A1 (en)	2024-05-22	2025-11-27	Ose Immunotherapeutics	Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025242836A1 (en)	2024-05-22	2025-11-27	Ose Immunotherapeutics	Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025245381A1 (en)	2024-05-23	2025-11-27	The Trustrees Of Dartmouth College	Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8607679D0 (en) *	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
GB9016299D0 (en) *	1990-07-25	1990-09-12	Brien Caroline J O	Binding substances

1993
- 1993-08-18 EP EP93919098A patent/EP0656946B2/en not_active Expired - Lifetime
- 1993-08-18 AT AT00127968T patent/ATE420178T1/de active
- 1993-08-18 DK DK05008358.3T patent/DK1589107T3/da active
- 1993-08-18 AU AU49497/93A patent/AU701578B2/en not_active Ceased
- 1993-08-18 JP JP50590394A patent/JP3444885B2/ja not_active Expired - Fee Related
- 1993-08-18 EP EP05008358A patent/EP1589107B1/en not_active Expired - Lifetime
- 1993-08-18 DE DE69334305T patent/DE69334305D1/de not_active Expired - Lifetime
- 1993-08-18 AT AT04077639T patent/ATE452207T1/de active
- 1993-08-18 EP EP04077639A patent/EP1498427B1/en not_active Expired - Lifetime
- 1993-08-18 ES ES05020889T patent/ES2325541T3/es not_active Expired - Lifetime
- 1993-08-18 AT AT93919098T patent/ATE203767T1/de active
- 1993-08-18 ES ES04077639T patent/ES2338321T3/es not_active Expired - Lifetime
- 1993-08-18 DE DE69330523T patent/DE69330523T4/de not_active Expired - Lifetime
- 1993-08-18 DK DK04077639.5T patent/DK1498427T3/da active
- 1993-08-18 DK DK05020889.1T patent/DK1621554T4/da active
- 1993-08-18 PT PT05020889T patent/PT1621554E/pt unknown
- 1993-08-18 DK DK93919098.9T patent/DK0656946T4/da active
- 1993-08-18 ES ES93919098T patent/ES2162823T5/es not_active Expired - Lifetime
- 1993-08-18 EP EP05020889A patent/EP1621554B2/en not_active Expired - Lifetime
- 1993-08-18 DE DE69334308T patent/DE69334308D1/de not_active Expired - Lifetime
- 1993-08-18 DK DK00127968T patent/DK1087013T3/da active
- 1993-08-18 PT PT04077639T patent/PT1498427E/pt unknown
- 1993-08-18 PT PT00127968T patent/PT1087013E/pt unknown
- 1993-08-18 AT AT05008358T patent/ATE452975T1/de active
- 1993-08-18 DE DE69330523A patent/DE69330523D1/de not_active Expired - Lifetime
- 1993-08-18 ES ES00127968T patent/ES2322324T3/es not_active Expired - Lifetime
- 1993-08-18 CA CA002142331A patent/CA2142331C/en not_active Expired - Lifetime
- 1993-08-18 ES ES05008358T patent/ES2338791T3/es not_active Expired - Lifetime
- 1993-08-18 AT AT05020889T patent/ATE427968T1/de active
- 1993-08-18 PT PT05008358T patent/PT1589107E/pt unknown
- 1993-08-18 DE DE69334275T patent/DE69334275D1/de not_active Expired - Lifetime
- 1993-08-18 PT PT93919098T patent/PT656946E/pt unknown
- 1993-08-18 WO PCT/EP1993/002214 patent/WO1994004678A1/en not_active Ceased
- 1993-08-18 EP EP00127968A patent/EP1087013B1/en not_active Expired - Lifetime
- 1993-08-18 DE DE69334258T patent/DE69334258D1/de not_active Expired - Lifetime
- 1993-08-18 EP EP09174252A patent/EP2192131A1/en active Pending
1995
- 1995-02-20 FI FI950782A patent/FI115462B/fi not_active IP Right Cessation
- 1995-06-06 US US08/467,282 patent/US5800988A/en not_active Expired - Lifetime
- 1995-06-06 US US08/471,780 patent/US5759808A/en not_active Expired - Lifetime
- 1995-06-06 US US08/471,282 patent/US5840526A/en not_active Expired - Lifetime
- 1995-06-06 US US08/466,710 patent/US5874541A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,739 patent/US6015695A/en not_active Expired - Lifetime
2001
- 2001-05-07 JP JP2001136457A patent/JP3660270B2/ja not_active Expired - Lifetime
- 2001-10-25 GR GR20010401895T patent/GR3037024T3/el unknown
2004
- 2004-12-08 FI FI20041584A patent/FI117975B/fi not_active IP Right Cessation
2005
- 2005-01-18 JP JP2005010359A patent/JP4414900B2/ja not_active Expired - Lifetime
2007
- 2007-02-28 FI FI20070170A patent/FI120404B/fi not_active IP Right Cessation
2009
- 2009-08-21 JP JP2009192382A patent/JP2009280608A/ja active Pending

Also Published As

Publication number	Publication date
EP0656946A1 (en)	1995-06-14
JP3660270B2 (ja)	2005-06-15
EP1621554B1 (en)	2009-04-08
GR3037024T3 (en)	2002-01-31
DK1621554T3 (da)	2009-08-10
JP4414900B2 (ja)	2010-02-10
ES2325541T3 (es)	2009-09-08
FI117975B (fi)	2007-05-15
US5800988A (en)	1998-09-01
ATE420178T1 (de)	2009-01-15
CA2142331C (en)	2010-02-02
EP1498427B1 (en)	2009-12-16
ATE452975T1 (de)	2010-01-15
DE69334258D1 (de)	2009-02-26
ES2338791T3 (es)	2010-05-12
JPH08500487A (ja)	1996-01-23
DK1621554T4 (da)	2012-12-17
JP3444885B2 (ja)	2003-09-08
US5759808A (en)	1998-06-02
PT1621554E (pt)	2009-07-13
JP2002053600A (ja)	2002-02-19
PT1589107E (pt)	2010-03-29
ES2162823T3 (es)	2002-01-16
DK0656946T4 (da)	2010-07-26
ES2338321T3 (es)	2010-05-06
US5840526A (en)	1998-11-24
DE69334305D1 (de)	2010-01-28
EP1087013A2 (en)	2001-03-28
PT656946E (pt)	2001-12-28
DE69330523T2 (de)	2002-03-28
PT1087013E (pt)	2009-04-15
FI120404B (fi)	2009-10-15
DK0656946T3 (da)	2001-11-05
FI950782A7 (fi)	1995-04-20
EP1589107A1 (en)	2005-10-26
DK1498427T3 (da)	2010-04-26
PT1498427E (pt)	2010-03-22
EP1498427A1 (en)	2005-01-19
JP2005170953A (ja)	2005-06-30
EP0656946B1 (en)	2001-08-01
EP0656946B2 (en)	2010-03-31
AU701578B2 (en)	1999-02-04
US5874541A (en)	1999-02-23
EP1589107B1 (en)	2009-12-23
ATE203767T1 (de)	2001-08-15
EP1087013A3 (en)	2001-11-28
FI20041584L (fi)	2004-12-08
ATE427968T1 (de)	2009-04-15
FI20070170L (fi)	2007-02-28
ES2322324T3 (es)	2009-06-19
EP2192131A1 (en)	2010-06-02
EP1621554A1 (en)	2006-02-01
JP2009280608A (ja)	2009-12-03
DK1087013T3 (da)	2009-05-11
DE69330523T3 (de)	2010-10-28
DE69334308D1 (de)	2010-02-04
DE69330523T4 (de)	2012-08-23
AU4949793A (en)	1994-03-15
FI115462B (fi)	2005-05-13
DE69330523D1 (de)	2001-09-06
CA2142331A1 (en)	1994-03-03
WO1994004678A1 (en)	1994-03-03
DE69334275D1 (de)	2009-05-20
ES2162823T5 (es)	2010-08-09
EP1087013B1 (en)	2009-01-07
FI950782A0 (fi)	1995-02-20
ATE452207T1 (de)	2010-01-15
EP1621554B2 (en)	2012-08-29
US6015695A (en)	2000-01-18

Publication	Publication Date	Title
DK1589107T3 (da)	2010-04-26	Immonuglobuliner uden lette kæder
AU5647896A (en)	1996-11-18	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ATE187494T1 (de)	1999-12-15	Multivalente einkettige antikörper
NO994998D0 (no)	1999-10-14	Fusjonsproteiner
FI965032A0 (fi)	1996-12-16	Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita
ATE510854T1 (de)	2011-06-15	Lineares, schweres antikörperkettenfragment vh- ch1-vh-ch1
ZA946767B (en)	1995-04-03	Monocional antibodies having property of causing apoptosis.
FI934963A7 (fi)	1993-11-10	CTAA 81AV78, monoklonaalisen 81AV78-humaanivasta-aineen tunnistama ant igeeni
NO911300L (no)	1991-04-19	Homoklonale antistoffer mot reseptor-fremkalte bindingsseter.